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ABSTRACT 
 
Nonprofit organizations vary in size and capacity.  They often start with a 
small group of passionate people brought together with a common focus.  Often 
their mission has a direct impact on the individual member or their communities 
and loved ones.  Today there are over 7,000 identified rare diseases and rare 
disease advocacy organizations representing patients and families that singularly 
are small in numbers.  In the aggregate, however they represent one-in-ten 
individuals worldwide.  This paper presents a case study of one rare disease 
advocacy organization from the perspective of an organizational consultant who 
is also a parent and advocate in the rare disease community.  Building upon the 
case study, the paper includes a review of existing research and literature and 
interviews with other leaders in the nonprofit and rare disease advocacy 
community.  The capstone examines leadership and other components of 
nonprofit organizations, including the role of the consultant, that help bring about 
transformative change and innovation within this sector.   
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CHAPTER 1 
INTRODUCTION 
Nonprofit organizations vary in size and capacity.  They often start with a 
small group of passionate people brought together with a common goal.  As of 
2012, there were over 1.5 million registered nonprofit organizations in the United 
States (Roeger, p.5).  Approximately three quarters of these organizations had 
operating budgets of less than $500,000 per year, many of them much smaller 
(2012, p.149).  Many small nonprofit organizations, often characterized as 
“grassroots,” share a similar profile in that they are led by members with a high 
level of passion and energy towards a singular mission.  Often times the mission 
has a direct impact on the individual or their communities and loved ones.   
Rare disease organizations are especially challenged as their small 
numbers draw on much more finite resources and the gravity and urgency of 
their mission have life and death implications.   In many cases they are 
represented by “kitchen-table” groups formed by parents of patients or even 
patients themselves and represent those impacted diseases that have been 
diagnosed less than 200,000 times (Dunkle, 2014, p.19).  Over 7,000 rare 
diseases have been identified, some with patient populations in single digits and 
many with less than one thousand identified patients.  Collectively, they 
represent more than 300 million people across the world. 50% of those 
diagnosed are children (Global Genes Alliance, 2015).  These organizations 
demonstrate extreme passion and resiliency.   To be truly effective, they must 
collaborate with other umbrella organizations such as the National Organization 
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for Rare Diseases (NORD), Global Genes, their governments, and universities 
such as the University of Pennsylvania’s Orphan Disease Center, research 
centers, pharmaceutical companies, and each other.  Despite these extreme 
challenges, many have grown to become model organizations that meet the 
increasing heavy load of their patient communities.  As research and drug 
therapies have advanced, so have the needs of their constituents.   
There has been little written with a specific focus on rare disease 
advocacy organizations.  Similar to other nonprofit organizations, their focus on 
mission and outcomes rather than financial returns call for unique attributes in 
their leadership, members and operations. This capstone offers a case study of a 
recent consulting engagement that took place with a rare disease organization.  
In addition to the case study, the capstone asks what separates the 
nonprofit sector from for-profit enterprises and explores the unique challenges 
and perspectives in the rare disease community.  It also explores the role of the 
consultant and organizational development practitioner when working with 
nonprofit organizations and includes a survey with leaders of other small 
nonprofit organizations, including past and present Board members, Board 
Presidents and Executive Directors of several rare disease and grass-root 
organizations who discuss the trajectory of their organizations and how they may 
have been positively or negatively impacted when working with consultants.  
These are presented over the next four chapters that are described below. 
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The DCO Case Study 
The case study recounts a recent consulting engagement with a small rare 
disease advocacy group. It includes my own history as a parent and advocate for 
a child with  Dyskeratosis Congenita (DC), a rare biological telomere disorder.  It 
shares the story of the consulting engagement with DC Outreach, Inc. (DCO) that 
I completed with classmate Bob Biglin and our advisor, Dr. Charline Russo as 
part of the University of Pennsylvania’s Master’s of Science in Organizational 
Dynamics - Organizational Consulting and Executive Coaching cohort program.  
The objective of this engagement was to help DCO’s leaders develop a strategic 
plan that was grounded on the past successes of the organization and leverage 
their strengths to help them identify a common vision that would build their 
organizational capacity and effectively lead their growing patient and caregiver 
community into the future.  
DCO was formed in 2006 by a small group of patients and parents with 
the following mission: 
Our Mission is to provide information and support services to families 
worldwide affected by Dyskeratosis Congenita and Telomere Biology 
Disorders to encourage the medical community’s research in finding 
causes and effective treatments, and to facilitate improved diagnosis 
by educating medical providers.  (Dyskeratosis Congenita Outreach, 
Inc.). 
This engagement had special meaning, as my oldest son Josh was lost to 
DC five years ago after battling this disease for over seventeen years.   When 
Josh was diagnosed with DC in 2002, he was one of less than 400 individuals in 
the world to ever have been diagnosed with this disease.  Since Josh’s 
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diagnoses, DC has been diagnosed in over 1,000 additional individuals.  
Although DC is considered an extremely rare “orphan disease,” it is believed that 
it goes undiagnosed more often than not.  The DC and biological telomere 
disorder (BTD) community believe that diagnoses will continue to grow as 
doctors become more educated and aware in identifying these underlying 
conditions as they encounter them when treating their symptoms (Olson, 2016).  
We found DCO to be an organization that has punched well above its weight as 
their past accomplishments have moved mountains, yet they are faced with 
much more to do with limited and tired resources. 
The Literature Review 
Building from the experiences of the DCO case study, the literature review 
includes a blend of peer-reviewed articles, books and on-line sources that 
explore prevalent factors towards building the organizational capacity and 
effectiveness of non-profit organizations.  Building from the experiences and 
learning of the DCO case study, the literature review focuses these observations 
to the following areas: 
• Rare disease advocacy organizations – a brief retrospect on the 
emergence of rare disease patient advocacy organizations and what 
factors separate these organizations from other nonprofits.  The history 
of the National Organization for Rare Disorders, a leading advocacy 
group representing thousands of rare disease organizations since the 
passing of the Orphan Drug Act in 1983 is presented to help frame the 
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unique challenges encountered by rare disease advocacy 
organizations.  
• The nonprofit/consultant relationship – An examination of what 
methodologies and applications are most effective when working with 
nonprofit organizations as a consultant and how these relationships 
have helped lead these organizations to grow in effectiveness, 
innovation and capacity.  Penolope Cagney’s book Nonprofit 
Consulting Essentials provides insight in regard to the consultant’s 
journey with nonprofits, and an analysis of the appreciative inquiry 
utilized with the DCO engagement is further examined. 
• Leadership and innovation in nonprofit organizations – qualities and 
challenges that distinguish the nonprofit sector from for-profit 
enterprises.  This section includes articles, research and insights from 
Peter Drucker and Frances Hesselbein that help set the foundation of 
the unique attributes found in the nonprofit sector.   It also examines 
research in regard to approaches in building organizational capacity 
and innovation with such organizations as the Association of Retarded 
Citizens (ARC) and studies with leaders from other small nonprofit 
organizations.  
Research Methodology, Assumptions, Data and Analysis 
In addition to my own experiences with DCO, Chapter four includes 
insights from leaders of other nonprofit organizations, including those from the 
rare disease community.  Those included in the interview process were some of 
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the most innovative and passionate people I’ve ever met.  Each of the interviews 
offered fascinating perspectives of the inspirational journeys that each of the 
represented grass-root organizations encountered as they continue to grow and 
help others cope, advance research and overcome obstacles that are encounter 
at the most personal level.   
Summary & Conclusions 
Chapter five provides a summation of observations and findings 
discovered in the case study, the literature review and the survey of other 
nonprofit leaders. The chapter presents questions and research opportunities to 
consider that were not within the scope of this study, but would be valuable to 
pursue.   The chapter concludes with my own reflections and thoughts in regard 
to the capstone experience and how this experience has influenced me as a 
parent, advocate, coach and consultant now and in the future. 
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CHAPTER 2  
THE DCO CASE STUDY 
The summer of 2016 was a rewarding time as my Penn OCEC Cohort V 
classmate Bob Biglin and I partnered under the supervision and guidance of Dr. 
Charline Russo to help an organization that has worked with few resources and a 
large mission.  Dyskeratosis Congenita Outreach, Inc. is a 501c(3) advocacy and 
support group that serves patients and caregivers of Dyskeratosis Congenita 
(DC), a rare disease diagnosed in less than one in every one million people in 
the world.  A recent article in Penn Today described DC as follows: 
DC, is a rare, inherited disease for which there are limited treatment 
options and no cure. Typically diagnosed in childhood, the disorder 
causes stem cells to fail, leading to significant problems including bone 
marrow failure, lung fibrosis, dyskeratosis of the skin and intestinal atrophy 
and inflammation. Patients are also at heightened risk of several types of 
cancer.  A common underlying feature of the disease is the presence of 
shortened telomeres. Telomeres are the structures that protect, or “cap,” 
the ends of chromosomes, but they tend to shorten with cell division and 
age, and can thus lose their protective functions. Many DC patients have a 
mutation in the DKC1 gene, which codes for a component of the enzyme 
called telomerase that helps maintain telomere length. Because 
telomerase is most essential in tissues that divide frequently, notably, 
epithelial tissues such as the skin, gut and lungs, this is where defects 
crop up in these individuals.  (Baillie, 2016).  
This engagement had special meaning, as my oldest son Josh was lost to 
DC five years ago after battling this disease for over seventeen years.   When 
Josh was diagnosed with DC in 2002, there were less than 400 others ever 
diagnosed with this rare telomere disorder.  Since then, DC has been diagnosed 
in over 1,000 other individuals. The DC and biological telomere disorder 
community believe that diagnoses will continue to grow as doctors become more 
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educated and aware in identifying DC manifestations in other conditions as they 
encounter them when treating their symptoms (Olson, 2016). 
In 2006 a small group of patients and caregivers affected by DC formed 
DC Outreach, Inc. with the following mission: 
Our Mission is to provide information and support services to families 
worldwide affected by Dyskeratosis Congenita and Telomere Biology 
Disorders to encourage the medical community’s research in finding 
causes and effective treatments, and to facilitate improved diagnosis 
by educating medical providers. (https://www.dcoutreach.org). 
 
My relationship with DC & DCO 
I am a parent of a child lost to DC.  Today those words are difficult to say 
and accept. They sadden and anger me.  They are part of my identity and serve 
to inspire how I choose to move forward. 
  Through the first fifteen years of Josh’s life, my wife Pattie and I had 
never met anyone, with the exception of doctors, who had any affiliation with this 
extremely rare condition.  Josh was our first-born.  As new parents, we felt 
confused and alone as we began understanding his condition and realizing his 
severe feeding issues, lack of growth, microcephaly and cognitive delays, and his 
phantom fevers in the middle of the night we were experiencing were not normal 
or healthy.  It took eight years before a definitive diagnoses was reached. DC is 
so rare, and there are so few data points, we found ourselves at the forefront of 
the unknown.  We resisted looking too far into the future and committed 
ourselves to living our lives with Josh in the moment.  We rarely thought of Josh 
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as sick or disabled.  To us he has always been and still is an integral part of our 
family. 
Josh’s first three years of life included severe feeding issues, a failure to 
gain weight and grow, and an understanding that he would need help throughout 
his life.  At the age of three Josh weighed only seven-teen pounds, had difficulty 
walking and talking and was constantly tired and sick.   At this time, we spent 
four months at the Seashore House at the Children’s Hospital of Philadelphia 
(CHOP).  After surviving some significant medical scares and setbacks, we were 
still without a diagnosis.  We brought Josh home the week before the Christmas 
of 1997.  He was stronger, walking and talking, and we could see that he would 
have a chance to live a viable and impactful life.  We still did not have a 
diagnosis; however, we knew his immune system was compromised and began 
a life of treatments and doctor visits between school and activities. 
When Josh was eight, Dr. Katherine Sullivan (“Dr. Kate” as we came to 
know her), an immunologist at CHOP, began to narrow down what she thought 
may be Josh’s underlying condition.  Dr. Sullivan along with the top geneticists at 
CHOP tested for multiple immunological disorders, syndromes and rare 
conditions.  Ultimately, through collaboration with Dr. Indergeet Dokal, a DC 
specialist from Hammersmith Hospital in England, we were able to pinpoint 
Dyskeratosis Congenita as Josh’s underlying diagnosis.   
When we learned of Josh’s diagnosis, we traveled to Hammersmith and 
met Dr. Dokal.  He was a resource to us through Josh’s life and remains a friend 
to the DC community and our family.  Having a diagnosis did not bring much 
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relief nor did it lessen the fear we were experiencing as a family.  We were still 
alone and Josh was only the 365th DC patient identified with DC that Dr. Dokal 
was aware of as he maintained a registry of DC patients from around the world.  
There were no support groups, massively attended walks or bike rides, 
broadcasts telethons, or Ice Bucket Challenges to spread awareness, raise 
money or provide connectivity for the few hundred people in the world diagnosed 
with this rare and little understood disease.   
What we did find was local support from our friends, family and the special 
needs community in Voorhees, New Jersey and later in West Chester, 
Pennsylvania, where we now live.  For fifteen years we managed Josh’s care 
along with raising our younger children Noah and Katie.  We were all affected as 
DC was part of our “normal” lives.  At this time, Josh’s care was manageable and 
with the exception of a few setbacks, his health was relatively stable.  Our focus 
was more on family, friends and wellness rather than the science or advocacy 
that comes with a rare disease. This all changed during the winter of 2010.   
One of the main complications for patients with DC is bone marrow failure.  
Josh’s bone marrow was tested and monitored each year and for the first fifteen 
years of his life, it remained relatively healthy and stable.  In early 2010 his 
annual bone marrow test revealed a decline in red-cell production and we began 
to see the first cracks in what had once been a manageable disease.    
In addition to being a member of his drama club and a year-round 
participant and camper at Bournelyf Special Camp, Josh also played Challenger 
League baseball.  The Challenger League included teams with children and 
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young adults with various physical and cognitive challenges along with “buddies” 
that helped them learn and perform the fundamentals of baseball.  As a parent, 
the league offered a great social connection with the special needs community.  
It also offered weekly games that were incredibly slow to watch.  One of the 
Challenger League rules is that each player has an at-bat in each inning.   
Thankfully the games were only three innings.  The last player each inning would 
clear the bases with a home run.   Every game ended in a tie.   During a game 
early in the 2010 season, Josh was the cleanup hitter.   When he hit his home 
run he struggled to get around the bases.  When we hugged in the dugout I could 
see he was exhausted and he asked if I could pull him out of the game.  I knew 
that we were heading towards a bad place.   
 
A few weeks later Josh had another appointment with his hematologist 
who was quickly learning about DC.   He had never heard of, none-the-less 
treated anyone, with this rare condition before Josh.  After several more tests, we 
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were told that Josh’s condition would only get worse and that the remainder of 
his life would be measured in months, not years.   
As a parent of a child with a chronic illness, I would often find myself up 
late at night searching online for new information about DC.  Shortly after 
realizing that things were not going to get better for Josh, I found a web-site 
called DC Outreach, a small support group for those dealing with DC.  By now, it 
had been eight years since we had a name for Josh’s disease.  I quickly saw that 
there was a patient community, albeit small, for others coping with this disease.  
DCO’s logo was “You are not alone”.  I briefly shared Josh’s story on the site and 
within a day I heard back from DCO’s President, Nancy Cornelius.  I learned that 
Nancy lived with her family in New York.  Nancy was diagnosed with DC while in 
her forties and she had a son, Charlie who was also diagnosed with DC.  At this 
time Charlie was a student and member of the diving team at Villanova 
University.  I also learned of another family who lived in New York, and whose 
father Seth, was originally from Lower Merion, Pennsylvania, and had a one-
year-old daughter just diagnosed with DC.  The next day I spoke with Seth and 
we realized that we grew up within a few miles from each other and albeit 10-
years apart, we went to the same high school (Seth was at Lower Merion during 
the Kobe Bryant years, about ten years after I graduated).  A few weeks later, 
Josh and I had lunch at Villanova with Charlie.  Suddenly we weren’t feeling so 
alone.   
We had found a community and soon expanded our network to doctors 
and others who were some of the few in the world that understood this disease.  
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Through DCO, we also learned that we did not need to go back to London for 
care.  Dr. Monica Bessler, a colleague of Dr. Dokal’s at Hammersmith Hospital 
had recently come to practice and chair the Hematology department at CHOP.  
Dr. Bessler along with her Resident colleague Dr. Tim Olsen, who succeed Dr. 
Bessler after her retirement and was a contributor to the DCO engagement as 
well as this study, were the very best people we could have met to support us 
through the final chapter of Josh’s life.  They were both extremely 
knowledgeable, caring and compassionate.  They were with us through Josh’s 
final months and days until his last breath.  Sadly, Josh’s health continued to 
deteriorate.  We knew with Dr. Bessler, Dr. Olson and Dr. Sullivan at CHOP we 
had access to the best possible care in the world for Josh.  At the age of 
seventeen, on November 18, 2011, Josh passed away.  DCO had become a 
lifeline for us as we confronted this disease, grieved our loss and gained the 
support and knowledge offered from this tight-knit community.   
Three years after losing Josh, I began working at the University of 
Pennsylvania.  Part of what drew me to Penn was continuing the Organizational 
Dynamics (OD) program. I had started in 2001, but stopped after taking three 
courses as Josh’s medical needs took precedent.  Working at Penn offered me 
the unique experience to become closer with the doctors and researchers that I 
had gotten to know over the years that helped Josh.  It also provided an 
opportunity to reengage in the OD program.  I rejoined the program with a 
greater focus than I had when I started it.  I wanted to help others who were 
dealing with similar challenges that I had as a parent and professional managing 
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an acute medical condition and facing the loss of a child.  The Organizational 
Consulting and Executive Coaching cohort program offered by the OD curriculum 
was the ideal place to pursue this mission. 
From parent and advocate to consultant 
Two years after losing Josh and shortly after beginning my work at Penn, I 
became a DCO board member.  DCO’s monthly Board calls were always 
awkward for me.  The Board meets monthly on the second Sunday night at 9PM.  
This time is difficult, but has worked best for its members as they are calling in 
from each of the US time zones and sometimes from the other side of the world.  
This was a large part of why I eventually left DCO’s board.  Sunday night is 
typically when my wife and I unwind together on our couch, so disrupting this to 
relive our DC experience became a hindrance toward coping with the loss of 
Josh.  I also felt many of the topics that consumed these calls, often late into the 
evening, were things that could be better resolved with other DCO members and 
were not reliant on my input.  The following e-mail to DCO’s Board President and 
Treasurer was difficult to write, but expressed my thoughts at this time. 
On Sat, Mar 12, 2016 at 3:01 PM, Microsoft Office 
User <bwf819@yahoo.com> wrote: 
Robin, Lisa - This morning I was on a training ride for the MDBR and 
as often happens, I found myself lost in my thoughts.  I want to share 
with you as we’ve gotten to know each other a bit over the years.  I 
apologize for the long note, but you’ve both been helpful to me over 
the last couple of years and I’d like to share this with you. 
 I admire both of you for your resilience and determination as you 
fight through DC and endlessly work to help others as well as 
yourselves.  Your energy and perseverance are truly inspirational. 
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I now find myself four + years since Josh passed away.  My son Noah 
is now older than Josh was when he passed and will be entering 
Millersville University this fall.  My daughter Katie is 15 and truly an 
exceptional student, dancer and young lady.  Pattie and I continue to 
grieve but now find ourselves thinking more about Josh’s life and less 
about what we went through managing a terminal disease.  It’s been 
a difficult road getting to where we are and I’m beginning to 
understand more now that it’s time to focus more on what’s in front 
of us and ahead of us while continuing to honor Josh’s memory.   
Over the last ten months, I’ve been engaged in a degreed executive 
coaching and Masters program at Penn.  When I accepted a position 
at the University, I took a large cut in pay, but was motivated to do 
so as I’ve always felt a strong closeness to CHOP and Penn, I also 
wanted to help other grieving parents or those with children with 
chronic  illnesses who have professional careers as I’ve experienced 
all of that myself and I found Penn offered me an opportunity to 
pursue that goal.  Now that I’m about half way through the program, 
I realize that I do enjoy coaching and I think I’ll be pretty good at it, 
but I need to figure out how to transition this into a career and also 
realize that it’s much broader than the initial goal that motivated me 
to start. 
I joined the DC Outreach Board last year following for a few 
reasons.   One was I had reached out to Dr. Bessler ad Dr. Olson 
who had treated Josh and was with us as he took his last breath to 
ask how I could help other DC families at Penn, she suggested I 
become involved again with DC Outreach.  I also was grateful for the 
support DC Outreach and in particular Nancy Cornelius who were 
with us as Josh’s health began to deteriorate and we began to 
understand that his condition was not going to get better. Lastly, I felt 
obligated as Josh’s Dad to honor his memory and help others.   
The challenge I’ve had and continue to have is that I’m stretched 
pretty thin.  I started a new position within Penn this past January, 
I’m also still active with the board for Josh’s camp, which is right down 
the street from where we live and includes families that we’ve 
become very close to throughout Josh’s life.  It’s also helpful to us 
that Pattie, Noah and Katie are all involved with the camp throughout 
the year.  Another challenge that has become more apparent is that 
it’s becoming more emotionally draining for me to actively participate 
in DC Outreach.  I feel that I contribute a lot with my board 
experiences and resources at Penn, but calling in on Sunday nights 
and other nights is a disruptive and difficult reminder to me as well 
as Pattie and our kids as we continue to move forward as a family.  I 
stopped calling into the family calls which are wonderful, after Josh 
passed away, as it was too difficult to listen to others going through 
what we had and I did not feel I could offer much hope, especially as 
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difficult as the last 18 months of Josh’s life was.  Whereas this was 
once a way to help me cope with grieving, it’s become more of a 
hindrance in moving through the grieving process.  That’s in large 
part why I’ve limited my participation to the monthly calls. I don’t feel 
I’ve been as good a board member as I should be and right now, I 
don’t think I can, it’s hard for me to say that, but it’s how I feel.   
I’d like to remain a friend and resource to DC Outreach.  I’m glad to 
continue to help as an advisor or maintaining relationships with Penn, 
but I don’t think it’s productive for me to continue on the Board.   
I will call into tomorrow night’s meeting as I have a few items on the 
agenda. I don’t want to make a big deal about this on the call, and I’d 
like to get your thoughts on how and if I can best contribute without 
being a full-fledged board member before doing anything “official”.   
I appreciate your friendship and hope that you can understand how 
difficult this decision is for me, but I think it’s one I need to make. 
Best,  
 Bruce 
 
After leaving the DCO Board, I wanted to maintain my connection with the 
organization.  The OCEC cohort has been a transformational experience for me 
as I realized I would want to eventually transition my career from that of a finance 
professional to a coach and consultant.  As part of the Cohort program, we were 
required to complete a consulting field experience.  I could not think of a more 
rewarding experience than working with DCO.  At this time I approached my 
classmate, Bob Biglin, with this idea and after we thought through an initial 
approach, we presented this plan to our advisor, Dr. Charline Russo.  
As a parent of a child lost to DC and who found help and support from 
DCO during the most difficult time of our lives, and as a former board member of 
DCO, I struggled with defining my role as a consultant.  I had known the Board 
members via phone and Internet, and even a few in-person contacts over the 
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past seven years. When Bob and I introduced our proposal to the Board 
members, I knew I needed to make the shift from DC parent and advocate to 
consultant.  I was concerned my emotions would get in the way, and would result 
in the transference of my own experience with DC and rare diseases.  I knew I 
needed to be objective and open myself up to the truths and experiences of other 
people.   Getting out of one’s own way is not an uncommon area of development 
for coaches and consultants, yet my concern was amplified as DC has had such 
a profound impact on my life and my immediate and extended family.  
Developing a new relationship with DCO’s Board 
Over the past several years, DC has been diagnosed more frequently and 
the patient pool continues to expand.  Consequently, DCO’s Board finds itself 
working with a small budget and often searching for expertise and resources that 
are needed outside of the DC families that they serve.  The Board consists of a 
small group of DC patients and caregivers, many physically and financially 
exhausted from the implications of managing a chronic illness.  Until recently, 
only those directly impacted by the disease were board members.  The disease 
has devastating implications to each patient’s health and the well being of the 
patient and their caregivers.  The current board members all shared a feeling of 
“burn-out” and felt they had so much to do with very little energy to continue to 
advocate and carry out their mission.  
Through Board calls and other interactions with DCO’s Board, 
transitioning my role as a board member to a consultant would be difficult for 
DCO’s Board members and me.  As Bob and I introduced the consulting 
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engagement to the Board during their August monthly Board Call, there was 
awkward silence.  I realized about halfway through our meeting that we did not 
do a very good job setting the table and jumped right into the content and 
approach of the consulting engagement.  This was in large part my own doing as 
I initiated the discussion, but forgot to introduce Bob to the other board members.  
This was the result of my own anxious energy and I realized we had lost our 
audience.  I stopped in the middle of our presentation and acknowledged that I 
had not set up our discussion appropriately.  We then took the time to introduce 
ourselves and asked each member what their thoughts and concerns may be as 
we outlined the proposal.  This followed with a much more robust discussion and 
we left the Board meeting with the promise they would get back to us in the next 
several days with a decision in regard to proceeding with the engagement.   
At this moment I realized, that although I knew I needed to manage myself 
carefully through the engagement and avoid assumptions based on my own 
experiences, I also needed to step back and breathe.  I needed to be very 
deliberate in my interactions with DCO and balance the experiences that I was 
bringing to this engagement, with objectivity and professionalism.  After the call, 
Bob and I spoke.  I shared my feelings with Bob and we both recognized even 
more clearly how much we needed each other to effectively move forward with 
DCO.   
Although maintaining a professional distance during the engagement with 
DCO presented a challenge to be managed, it was also an asset in truly 
understanding and helping the organization.  As described in Edgar Schein’s 
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Humble Consulting, I had entered the DCO engagement already with a “Level 
Two Relationship”, that is a more personal, more trusting and open relationship 
with DCO board members than typically experienced from an outsider’s point of 
view (2016, p. 15). Schein describes humble consulting as a consulting 
relationship that presumes the consultant is committed to being helpful, bringing 
a great deal of honest curiosity, and having a caring attitude.  Even though I had 
an extensive relationship with DCO in the past, working with them as a 
consultant was new and it was important that Bob and I engaged in what Schein 
describes as the “personalization process”.  We needed to get to know DCO and 
understand their true challenges by demonstrating genuine curiosity, caring and 
a commitment to helping.  This process proved valuable in establishing a 
relationship-building process that would be used throughout the engagement and 
would lead to interactions that the client would find immediately helpful (2016, p. 
13).  I needed to recalibrate and re-personalize my relationship with DCO.   
Building this relationship and establishing an awareness of how my 
relationship with DCO was influencing this new engagement was an important 
step in helping DCO understand their capacity for change and growth.  As our 
work progressed, I was able to find a middle ground and balance what had 
become a very personal and close relationship with some of DCO’s board 
members over the years.  The new context of our relationship enabled me to 
avoid becoming what Schein refers to as “content-seduced” and better manage 
myself to focus on the various processes that were occurring between DCO’s 
Board members, Bob and me (2016, p. 20).   
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This balance was first challenged when Bob and I first arrived at DCO’s 
Camp Sunshine Retreat, where we were to present DCO’s vision and strategic 
plan to their Board, families and medical advisors.  When we arrived at Camp 
Sunshine, we were invited to have dinner with the camp families.  We agreed 
that it would be rude not to interact with the families and we enjoyed meeting 
them and learning more personal stories of their coping with DC.  This was a 
critical part of the personalization process.   
The next day, after Bob and I presented the DCO vision and plan to its 
members, we were invited to be included in a camp picture with families, doctors 
and others at Camp Sunshine.  I decided that I was not comfortable doing this.  I 
felt that the camp and its pictures were to provide hope and encouragement for 
those coping with DC, and not a place to memorialize those who had been lost.  I 
was stuck in-between the role of a consultant who maintained objectivity with our 
client and the role of a grieving parent amongst those who were currently 
survivors of DC.  My relationship with DCO has changed since losing Josh and 
even more so now as I’m looked upon as a consultant.  I was concerned that 
joining in with the families who were celebrating their time together at Camp 
Sunshine would create more confusion in regard to these roles.  I believe 
stepping away at this time was appropriate. 
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Determining an approach 
 Understanding DCO’s history and being familiar with other rare disease 
organizations was helpful in evaluating what we believed would be the most 
effective approach in structuring our engagement.  One option was to follow a 
conventional problem-based approach in which we would survey the board for 
their objectives, evaluate their present state, develop a gap analysis, and then 
help them identify a plan to move forward.  From our initial discussions with the 
Board, it became clear that there were much deeper challenges to be addressed 
if they were to successfully develop and execute a strategy focused on 
expanding their capabilities and outreach.  Our initial evaluation of the Board and 
the organization’s readiness to engage in a more comprehensive strategy 
development exercise revealed the following: 
  Board Fatigue:  Like many patient advocacy organizations, DCO had been 
built on the energy and commitment of a core group of patients and their 
families.  None of the current Board members had professional experience 
as a non-profit leader and most had limited or no professional managerial 
22 
 
 
 
experience.  Commitment, a passion for their mission, and a high degree 
of tenacity had fueled their growth and success.  After years of supporting 
patients and families, while also managing the emotional and physical 
challenges of dealing with the disease themselves, many of the Board 
members were exhausted and becoming dispirited at the new challenges 
they were facing.  A growing need for their services, lack of funding and 
challenges in raising funds, and lack of success in recruiting more active 
engagement amongst the organization’s membership were all areas that 
would require vision and energy.    
  Absence of a coherent vision of the future for DCO:  Through our 
conversations with the Board collectively and individually, it became clear 
that a vision for the future of the organization was lacking.  While some 
individual members had general thoughts about the organization’s 
potential future, most were focused on serving the present needs of their 
members.  Consequently, collective thought had not been given to the 
future.  Through discussions, we learned that Board members were so 
consumed with delivering services to current and new members – 
everything from assembling, packaging and posting informational 
welcome packets, to managing the website and social media presence, 
and hosting a monthly family teleconference – it was apparent that there 
was no time or energy to plan for the future.  
  Lack of confidence in their skills as organizational leaders:  The absence 
of formal non-profit managerial skills, training and experience, combined 
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with pressures of meeting current needs of members, left the organization 
lacking confidence in its own ability to envision a thriving future.  It was 
critical that they had the opportunity to step-back, assess their current 
state and understand the existing internal and external influences that 
would enable them to lead the organization on a journey to achieving that 
vision.  
  Lack of a conscious appreciation for what they had already accomplished:  
During our initial discussions, we were surprised to observe that there did 
not seem to be a conscious awareness of the magnitude of what the 
organization had accomplished since it had been founded.  As third 
parties looking in, we were surprised and impressed to see what a group 
of committed patients and families had accomplished with minimal non-
profit training or experience, and relatively small amounts of funding.   
Since its formation in 2008, DCO has formally registered as a 501 c(3) 
non-profit; established a global patient directory; recruited a medical 
advisory board comprised of internationally accomplished researchers in 
the field of genetic orphan diseases; grown the organization’s membership 
to over 400 members from five countries; held a biennial camp for DC 
families; and published a 400+ page medical diagnostic and clinician 
guidelines manual.  While everyone we spoke with acknowledged these 
accomplishments, we did not believe that they fully comprehended the 
magnitude and importance of their success.  Our initial take-away was “if 
they can do this as a layman’s Board with no formal non-profit training, 
24 
 
 
 
imagine what would be possible if they were able to develop their skills in 
leading a mission based organization!”   
From these initial observations - Board fatigue, a lack of a future vision, 
low self-confidence, low appreciation of previous accomplishments – we 
developed a set of priorities that we thought were critical to the success of this 
project: 
  Emphasize the accomplishments of the organization to help build their 
self-confidence. 
  Devise and accompany the Board on a journey of discovery, helping them 
to understand how they can leverage the strengths they currently have, 
while building new capability with additional training and support.  
  Help them step back from the day-to-day firefighting, which consumed so 
much of their time and energy, to create the perspective to envision the 
possibilities for the future of DC Outreach.  
  Work with the Board to help them prioritize which activities should be 
continued, which should be stopped, and to consider who they can enlist 
help from in the broader organization to share the workload.  
Bob and I were influenced by what authors Sarah Lewis, Jonathan 
Passmore and Stefan Cantore present in their book, Appreciative Inquiry for 
Change Management (2011) as the “SOAR” model.   SOAR is an acronym for 
Strengths, Opportunities, Aspirations and Results (2011, p. 189).  The strategic 
planning process needed to be inclusive and as consultants, we needed to 
facilitate a process that was owned by DCO’s leaders and members.  We 
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decided to incorporate David Cooperrider’s Appreciative Inquiry (AI) model which 
is described on Case Western’s Appreciative Inquiry Commons website as: 
The cooperative search for the best in people, their organizations, 
and the world around them.  It involves systematic discovery of 
what gives a system “life” when it is most effective and capable in 
economic, ecological, and human terms.  AI involves the art and 
practice of asking questions that strengthen the system’s capacity 
to heighten positive potential.  It mobilizes inquiry through crafting 
an “unconditional positive question” often involving hundreds or 
sometimes thousands of people. 
(https://appreciateiveinquiry.case.edu/intro/definition.cfm). 
With those priorities in mind, we felt that an approach informed by 
appreciative inquiry would provide the appropriate framework for creating 
momentum and energy for the organization and its leadership, through a 
strengths-based focus.  We planned to employ an inquiry-based methodology to 
focus on strengths and opportunities and help DCO’s Board move beyond 
perceived weaknesses and threats (Stavros, Cooperrider, & Kelly, 2003, p.6). 
Appreciative Inquiry and DCO consultation  
 Based on our initial discussions with the DCO Board, our assessment of 
the current state of the organization, and the Board’s objectives regarding a 
future strategy, we developed an engagement design built on the principles of 
Appreciative Inquiry.  Although we were not able to convene a more traditional 
multi-day Appreciative Inquiry workshop, we were able to use those same 
concepts and constructs, while working within the time, geographic, and logistical 
constraints we faced.  The engagement consisted of four major phases: 
1. Stakeholders and Questions: We introduced our engagement process to the 
Board during a board meeting.  This discussion included an overview of the 
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Appreciative Inquiry approach, a list of proposed questions for interviews and a 
rough timeline for the engagement (Appendix A).   
2. Interviews & surveys:  These included thirty individuals who represented 
patients, families, board members, doctors, researchers, leadership from 
partner organizations, and the pharmaceutical industry.  We also conducted a 
prioritization exercise with the Board to agree on a set of questions that we 
would use for the interviews and surveys to be conducted with these 
stakeholders.  Based on discussion with DCO’s Board, we derived the 
following sets of questions for three different sets of stakeholders: 
DCO Board members, patients and caregivers – this group included 
eight current and prior members of DCO’s Board and eleven other DCO 
patients and caregivers from the United States, Canada, New Zealand 
and Sweden. 
a. What are you most proud of that DCO has accomplished? 
b. When DCO is at its best, what are the core factors or strengths that 
give the organization life? 
c. In your ideal world, what does DCO look like five years from now?   
d. From your vision of DCO in five years, what do you see as the most 
important attributes & skills for its Board members? 
e. Partnerships have proven to be very important to DCO.  What existing 
partnerships should be strengthened and what new partnerships 
should be pursued to support the five-year vision? 
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DCO Doctors – this group included all six members of DCO’s Medical 
Advisory Board and two other doctors who have treated DC patients.   
a. What would you consider to be the most important areas for DCO to be 
engaged with in the medical and research communities in the next five 
years? 
b. What non-DC conditions should DCO consider when exploring 
possible partnerships? 
c. If DCO was able to sponsor research, what areas of research do you 
believe would be most important? 
DCO Partner Organizations – this group included the leadership of five 
rare disease organizations and support groups that included Penn’s 
Orphan Disease Center, Global Genes, Camp Sunshine, Smart Patients 
and Repeat Diagnostics.  In addition to the DCO partner organizations, we 
also interviewed a highly respected CEO of an orphan disease 
pharmaceutical company. 
a. As a partner with DCO, what core competencies and strengths do you 
feel DCO contribute and can build upon? 
b. How does DCO best compliment your organization and how could they 
best expand their influence with you in the coming years? 
c. What attributes do other rare disease advocacy groups demonstrate 
that have been valuable in growing a successful partnership with your 
organization.  How can DCO increase their effectiveness in these 
areas? 
28 
 
 
 
d. Are there other organizations that you have worked with that you 
believe would be a good partner for DCO?  Who are they and would 
you be open to facilitating an introduction? 
3. Synthesis and reporting: Using the data acquired during the interviews, we 
assessed and synthesized the feedback, developing key themes for each 
major constituency, and then developed recommendations to share with the 
Board and present to the DCO community who would be present at one of 
their biennial camp sessions at Camp Sunshine in Casco, Maine.  The camp 
session would also provide the venue for us to facilitate a conversation 
amongst the community to help refine our broad strategy recommendations 
into a more specific action plan.  The key themes for each constituency are 
listed in the body of the presentation made at Camp Sunshine (Appendix B).  
4. Create a detailed action plan:  The final step of the engagement was to 
incorporate everything we had learned through all of our interactions with the 
DCO community, and create an action plan for the organization to use.  We 
primarily focused on creating a roadmap of specific activities and milestones 
that the Board could follow to kick-start their efforts.  The detailed action plan 
was delivered to the Board (Appendix C).  Along with a detailed action plan we 
also provided the Board with a draft of a “Call to Action” memo for their 
constituents as well as a draft job description for an Executive Director.  
Throughout these interviews and surveys we found alignment in what 
DCO members and others had identified as their most profound 
accomplishments.   Almost every DCO family and medical community member 
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interviewed identified the publication of DC’s Clinical Guidelines as their biggest 
accomplishment.  They also spoke about the ongoing support DCO provides 
through monthly parent and patient calls with members of their own medical 
advisory committee and others to help families fighting DC.  Camp Sunshine and 
the simple fact that they’ve accomplished so much with so little were recurrent 
themes that members of the DCO community reflected upon in their responses.   
DCO members described the organization’s biggest strengths.  Strengths 
included tremendous commitment from a dedicated and responsive medical 
advisory board.  They also expressed that DCO was at its best when members 
pulled together to help a family under difficult circumstances, and their ability to 
work together with a common focus and goal.  These strengths were 
demonstrated during their participation at medical conferences and building 
strategic partnerships to advance their mission.  DCO’s board and its members 
were aligned in recognizing the valuable work they’ve done on behalf of their 
families.   
Our interviews and data collection outlined a common vision and 
aspirations that included casting a broader net in identifying patients with DC and 
those with other telomere biological disorders.  It also identified opportunities to 
build impactful relationships with the pharma community as well as taking a more 
active role in influencing research towards treatments and ultimately a cure for 
DC.  These aspirations were broken down into four categories as presented 
below: 
30 
 
 
 
  
  
Members also identified differences and alignments between those who 
are adult patients with DC and those who are caregivers, mostly parents that are 
managing and living this illness through their children.  
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While identifying how DCO would build upon its history of accomplishing 
so much with so little, their community also realized that the organization needed 
to grow to meet these aspirations.  Member engagement, expanding their 
network to individuals with valuable skills and commitment that were not as 
directly impacted with the disease, and focused fundraising were all aspirations 
that needed to be acted upon to build on their success.  The vision included 
moving from a patient-driven group to an effective professional advocacy 
organization and it was agreed that a seasoned Executive Director who could 
work with a board focused on DCO’s strategy and a committee structure as 
outlined below would be a critical factor towards moving forward.   
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Although ambitious, the plan presented generated energy and a sense of 
achievability from the Board and DCO members when presented at the Camp.  
DCO’s Vice President, Rachel Godfrey, stood up after we presented their vision 
and proclaimed that she felt “DCO was so close to meeting these challenges, we 
just need those in this room to help!” 
As we developed these thoughts and ideas into an articulate presentation, 
we began discussing what we thought would be needed for DCO to successfully 
move forward.  We shared a concern that the current board members did not 
have the capacity or experience to organize these ideas into an actionable plan.  
We decided we needed to be prescriptive in outlining the tactical steps that the 
board would review, prioritize and execute upon.  We also provided DCO with a 
draft job description for an Executive Director as well as a “Call to Action” to help 
them expand upon their member’s engagement.  This went beyond the initial 
scope of our engagement, but we agreed this would be critical to help DCO move 
forward.  We discussed this plan with DCO and they were grateful for the 
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roadmap we provided.   DCO’s President, Robin Huiras expressed this as she 
shared the following with us in an e-mail (October 10, 2016): 
Hi Bob & Bruce,  
Thanks so much for this.  
I was thinking today about the qualities that someone would need 
to have to run the group (there's so many).  And it's so very nice to 
have you and Bruce thinking about this for me. It's just so kind of 
you and I thank so for your time and energies helping DCO. 
You both have given us a vision to work toward. It's not something I 
knew was missing, But now that it's there, the path forward makes 
so much more sense. Your work and ideas are so appreciated. 
Take care, 
Robin 
 
Next steps with DCO – coaching a new President 
Shortly after we returned from Camp Sunshine, DCO’s president, Robin 
called me to let me know she would be stepping down from DCO’s board at the 
end of the year.  I was not surprised by Robin’s news, as I could see she was 
physically and emotionally struggling from the disease while at the camp.  Robin 
also told me that Katie, someone who had been a less-active board member 
whose son received a bone marrow transplant two years ago would be stepping 
into the role of Board President.  I had interacted with Katie a few times over the 
past several years and had met her for the first time at Camp Sunshine.  Katie 
seemed to have a lot of energy and passion towards helping others with DC. At 
camp, Katie and I had a conversation about her desire to be more active with 
DCO.  She was struggling to understand how she could contribute.  I shared with 
her some of my thoughts regarding the vision and what would be required to 
make it happen.  At this time I realized that Bob and I had to help DCO’s Board 
members and families find their story.  It’s a story many of them already know, 
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but we provided a framing to tell it and make it an effective tool in building 
resources and energy to make it happen.    
After receiving the call from Robin and reflecting on my interaction with 
Katie, I realized there was still much I could do to help Katie in her new role and 
contribute towards her ability to successfully lead DCO towards their vision.  The 
next weekend, I reached out to Dr. Russo and shared my thoughts about where 
we were in our engagement and how I could continue to be of help to DCO.  I 
realized that I could not return to DCO’s board, as the reasons I left still remain.  I 
also realized that I could continue to help in a more focused and targeted way.  I 
asked Dr. Russo for her thoughts if I moved my relationship from a consultant to 
DCO to a coach for their new President, Katie.  As we discussed this idea, we 
agreed this would be a natural extension of our consulting engagement.  When I 
approached Katie with this proposal she was very excited and energized to move 
forward.  We agreed to begin formalizing this arrangement and as I write this 
capstone, we are excited to move forward with this engagement.  This will serve 
as the coaching field experience in completing my MSOD by June 2017.   
As I write this capstone, Katie and I are three months into our coaching 
engagement.  This has provided an opportunity to help Katie see herself as a 
leader and define a vision that will enable DCO to continue to build on its 
previous successes.  This is an especially challenging time for rare disease 
advocacy as our country’s new President and his administration are targeting 
significant budget cuts towards federal research, namely the National Institute of 
Health (NIH).  The role of DCO’s leader is even more challenging as it will require 
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even greater collaboration with other rare disease organizations, the 
pharmaceutical industry and other research centers.  Also, as DCO has recently 
transitioned this role to Katie, it will be important that they are able to move 
forward in their research, fundraising and advocacy initiatives with great urgency, 
while keeping DCO’s patients and caregivers front and center.  Katie is taking on 
this role at an especially challenging time and I have been learning with her as a 
coach and advocate.  
Following our engagement with DCO, I spoke with other Executive 
Directors of nonprofits, friends, colleagues and just about anyone who would 
listen to our adventures over the summer.  I realized that the DCO story is not an 
unusual one.  There are thousands of other rare disease and other grassroots 
organizations that struggle with thin resources and ever-growing needs.  As I 
near the end of Penn’s Master’s Program in Organizational Dynamics, I’ve 
realized that the nonprofit community is an area that provides enormous 
opportunities to utilize many of the skills I’ve learned throughout my career as 
well as life experiences and my ongoing education.  This has created an exciting 
vision that I am currently developing and that this capstone explores further.   
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CHAPTER 3 
LITERATURE REVIEW  
Working with DCO during the summer of 2016 along with my personal 
experiences in the rare disease community has inspired me to go further in 
understanding and researching the influence of leadership and the role of the 
consultant in building organizational capacity and achieving outcomes in small 
non-profit organizations with a particular focus on rare disease advocacy. 
Building from the experiences and learning of the DCO case study, this literature 
review applies these observations to the following areas: 
• Rare disease advocacy organizations –what factors separate these 
organizations from other nonprofits.  
• The nonprofit/consultant relationship –what methodologies and 
applications are most effective when working with nonprofit 
organizations as a consultant and how these relationships have helped 
lead these organizations to grow in effectiveness, innovation and 
capacity.  
• Leadership and innovation in nonprofit organizations – qualities and 
challenges that distinguish the nonprofit sector from for-profit 
enterprises.  
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Each of these topics are analyzed with the DCO case study in mind and 
the case study serves as a data point in comparing and contrasting the theories 
and arguments presented. 
Rare disease advocacy organizations 
 Rare disease advocacy organizations, such as DCO share the 
commitment and passion that can lead to innovation and increased capacity.  
These organizations also have unique challenges when compared to larger 
organizations in the nonprofit sector.  As demonstrated in the DCO case, Boards 
and volunteers of rare disease advocacy organization often consist of patients 
and caregivers that are stretched in many ways.  One reality that amplifies these 
challenges is that the members of rare disease advocacy organizations are 
literally fighting for their lives.  This leads not only to commitment, but also 
urgency.  This is often exacerbated as by definition, these groups often lack size, 
scale and a forward looking perspective that would enable greater capacity for 
strategic leadership and vision.  They are truly living their lives and managing 
their organizations on a day-to-day and moment-to-moment basis.   
Featured in the medical journal Science, Dr. David Fajgenbaum, who’s 
inspirational and incredible journey as doctor, researcher and rare disease 
patient is described in greater detail in the next chapter of this capstone, 
describes his work in fighting Castleman’s Disease.  Dr. Fajgenbaum is the 
founder and leader of the Castelman Disease Collaborative Network, whose 
mission is to prioritize and coordinate research into this disease.  Dr. 
Fajgenbaum describes his passion as “intensely personal” (Thomas, 2017, p. 7).   
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Dr. Fajgenbaum’s friend Josh Sommer describes Fajgenbaum as the 
“quarterback” for Castleman’s disease and maintains that “every rare disease 
needs… someone to marshal the team, harness the resources, and lay out a 
game plan…People have to put their faith in this person”  (Couzin-Frankel, 2016, 
p. 214).  Fajgenbaum’s journey exemplifies just how limited resources are for 
rare disease organizations as they address problems that are extremely complex 
and are literally life-or-death. 
 As rare advocacy organizations struggled with limited resources and a 
patient base too small to be attractive to those in the for-profit sector to take 
notice, transformational change was needed to bring these groups together to 
garner attention towards a collective mission.  The history of National 
Organization for Rare Disorders  (NORD) and the Orphan Disease Act offer other 
rare disease advocacy groups and those who look to partner with them as 
consultants, insight into what makes these organizations special and unique. 
 NORD is a nonprofit (501(c)(3)) organization dedicated to patient 
advocacy and individuals with rare diseases and the organizations that serve 
them.  NORD’s mission is committed to the identification, treatment, and cure of 
rare disorders through programs of education, advocacy, research, and patient 
services (https://rarediseases.org/about/what-we-do/history-leadership).  
Founded in 1983 through its advocacy of the Orphan Drug Act of 1983, NORD is 
the leading rare disease umbrella organization in the United States.  Their motto 
of “Alone we are rare.  Together we are strong,” serves to frame their mission 
and vision of: 
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• A national awareness and recognition of the challenges endured by 
people living with rare diseases;  
• A culture of innovation that supports basic and translational research to 
create diagnostic tests and therapies for all rare diseases; 
• Access for all patients to the diagnostics and therapies that will extend and 
improve their lives;  
• A regulatory environment that encourages development and timely 
approval of safe effective diagnostics and treatments.   
In 2014, the Journal of Orphan Drugs: Research and Reviews, published 
A 30-year retrospective: National Organization for Rare Disorders, the Orphan 
Drug Act and the role of rare disease patient advocacy groups by Mary Dunkley.  
The retrospective recounts the origin of a formalized rare disease community that 
was driven by a few-high profile individuals.  Two of these individuals were 
Marjorie Guthrie, the widow of legendary folk singer Woody Guthrie, who died 
from the rare Huntington’s Disease, and actor Jack Klugman (2014, p. 20).   
Actor Jack Klugman, who starred in the popular television drama Quincy, 
MA was influenced by his brother, Maurice Klugman who was a producer on the 
show, and suffered from a rare form of cancer.  In 1981, Maurice created a story 
depicting a young man suffering from Tourette’s Syndrome and the orphan drug 
problem.  When the episode aired, it sparked a firestorm of interest, particularly 
from individuals and families affected by rare diseases. In describing the episode, 
the Washington Post Wongblog depicts the following in an article paying tribute 
to Jack Klugman when he died in 2012: 
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In a fit of pique, Jack Klugman hit upon a novel idea.  He and his brother 
wrote a second Quincy episode, this one revolving around an orphan drug 
bill that was being held up by a heartless (fictitious) senator.  In a pivotal 
scene, Quincy confronts the senator in his office and demands that he 
look out the window.  Peering down, the senator sees a huge crowd 
gathered with signs that read “We Want the Orphan Disease Act” and the 
Senator relents.  To shoot the scene, the show’s producers hired 500 
extras who really did suffer from rare diseases….  Hatch (Senator Hatch, 
a real-life congressman who was blocking the bill) too relented.  Thanks to 
Klugman, the Waxman-Hatch Orphan Drug Act became law in 1983.  It 
has been a remarkable success.  The FDA has approved more than 300 
orphan drugs, with 1,100 more under development (in 2012). 
By definition, each rare disease advocacy organization is an 
underrepresented group with critical needs and hopes.  Collectively, they 
represent over 7,000 diseases and 300 million people.  Umbrella organizations 
like NORD have brought influence and power with numbers.  They facilitate 
innovation to rare disease communities, including influence with legislation and 
pharmaceutical companies as well as the globalization of resources.   
The nonprofit/professional relationship 
Recognizing and understanding the unique strengths and challenges 
presented to nonprofit organizations informs the practitioner in how to best help 
mission-based organizations. Penelope Cagney examines the unique 
relationships that consultants and practitioners experience when working in the 
nonprofit sector in her 2010 book Nonprofit Consulting Essentials. Cagney writes, 
“Nonprofits have a range of consulting needs that differ from those of their for-
profit counterparts… They must work with consultants who know how to work 
with them – who can use nonprofit strengths to advantage and shore-up their 
weaknesses, who respect their uniqueness and are aware of how they differ from 
business – consultants who know when it is appropriate to apply for-profit 
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thinking but also when it is best to develop their own (2010, p. 1).”  Cagney refers 
to much of what Peter Drucker has observed in regard to the unique strengths of 
nonprofit organizations, she quotes Drucker, “The Girl Scouts, the Red Cross, 
the pastoral churches – our nonprofit organizations – are becoming America’s 
management leaders.  In two areas, strategy and effectiveness of the board, they 
are practicing what most American businesses only preach.  And in the most 
crucial area – the motivation and productivity of the knowledge workers – they 
are truly pioneers, working out the policies and practices that business will have 
to learn tomorrow” (2010, p. 2). 
 The DCO case demonstrated that unlocking the inherent passion and 
strengths that are found in the nonprofit culture presents a unique challenge to 
the consultant.  Cagney describes the “… boundless passion found in nonprofits 
is a great asset but can also be a handicap.  In the extreme it can seem to defy 
reason… As a result it is possible for board and staff to view with suspicion 
anyone who doesn’t share their commitment” (2010, p. 13).  Prior to taking on the 
role of a consultant with DCO, I was a member of this community and remain an 
advocate as someone who had been directly impacted by this terrible disease.  
Although my history with the group and passion towards its mission were not 
something I ever felt I had to prove, I understood that my role as a consultant 
would be much different than the role of a parent.  Part of the challenge 
throughout the engagement was to manage myself effectively, listen without 
prejudice while still maintaining high levels of empathy and unconditional positive 
regard.  In Flawless Consulting, Peter Block stresses the power of authenticity in 
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the consulting relationship as he writes “… Acting authentically is the most 
powerful thing you can do at every stage of the process” (2011, p. 44).  Carl 
Rogers stresses the power of empathy in On Becoming a Person as he writes 
“…if I can form a helping relationship to myself – if I can be sensitively aware of 
and accept my own feelings- then the likelihood is great that I can form a helping 
relationship toward another”  (1995, p. 51).  Sorting through my own experiences 
and feelings in regard to DC and DCO was an important step in effectively 
working with DCO.  Cagney’s book addresses the unique relationship of the 
consultant with nonprofit organizations.  
 Cagney’s philosophy often references the humble consulting relationship 
as described by Edgar Schein (2016).  Schein emphasizes that to truly 
understand organizations where problems are complex and ambiguous, which is 
especially true in organizations that are measuring outcomes based on their 
impact toward mission rather than primarily on dollars and cents, there must be a 
degree of “personalization” that the consultant offers and experiences to truly 
help an organization (2016, p. 7).  In describing personalization, Schein 
describes a “Level 2” relationship that goes beyond a transactional relationship 
between the consultant and client, but also avoids the trappings of a more 
intimate relationship that may go beyond what is truly effective in understanding 
and helping an organization.  Schein describes the Level 2 relationship as the 
consultant not opening the door to anything personal, but rather, creating a 
climate where the client will be able to become trusting to a degree where they 
may reveal what is really happening within an organization.  He characterizes the 
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consulting relationship as one that includes a level of personalization, which he 
describes as the “fundamental process by which we move from being strangers 
to becoming acquainted, getting friendly, being teammates, getting connected, 
and in various ways developing the higher level of trust and openness that I am 
calling the Level Two relationship” (Schein, 2016, p. 111).   
Schein’s approach resonates in regard to the dynamics described by 
Cagney as they both encourage the consultant to avoid becoming “content 
seduced” (2016, p. 20).   Rather, the helping consultant enables the organization 
to build its own capacity.  Cagney and Schein focus on the consulting process 
rather than simply the outcome.  This was particularly relevant in the DCO case, 
as their needs went beyond problem solving, but rather, they had a more 
complex need of building organizational capacity. 
  “The Future of Organization Development in the Nonprofit Sector” 
provides a study that seeks to inform organizational development practitioners in 
regard to how they can most positively impact nonprofit organizations 
(Wirtenburg, 2007).  The article outlines the findings of a survey of 235 nonprofit 
executives as well as a dozen corporate leaders seeking their input in regard to 
how organization development practitioners could most effectively (2007, p. 180): 
• Align the organizational development field more closely with the 
substantive challenges facing the nonprofit sector;  
• Add value by leveraging the strengths organizational development can 
offer nonprofit organizations; 
• Blend theory with practice; and  
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• Create a significant and positive impact on civil society by infusing values 
and process expertise that are the building blocks of the interdisciplinary 
field of organizational development.   
The survey revealed that the nonprofit organization leaders identified 
development and management of emerging leadership as the most neglected 
critical activity in their organizations.  Respondent’s specifically mentioned limited 
resources, especially funding their organization’s small size, as responsible for 
the difficulties in developing leadership capacity.  The responses also indicated 
that nonprofit organizations must continually change to sustain and achieve their 
mission.  One respondent wrote, “Determining (and) communicating vision, 
observing others in the system as they attempt to translate vision into action, 
coaching for action, educating to overcome resistance, identifying the important 
dissatisfactions, (providing) reasons for change, and providing ongoing 
communication about those dissatisfactions” were all components in driving 
sustainable changes to meet nonprofit missions” (2007, p. 185-186).     
The themes of leadership, innovation and transformation, vision and 
collaboration are common throughout the literature focused on helping nonprofit 
organizations.  Although none of these attributes or outcomes are unique to 
nonprofits or rare disease advocacy organizations, this sector is challenged at a 
higher degree than many of their nonprofit counterparts.  Not only by size and 
skill levels within the organization, but as was demonstrated in our work with 
DCO, just talking about the disease was difficult for those directly impacted by 
DC.  Demonstrating empathy and positive regard proved to be of even greater 
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emphasis when working with a rare disease advocacy organization.  This was 
particularly challenging while maintaining a professional and consultative 
relationship between the organization and the consultant.  When planning the 
DCO engagement, Dr. Russo, Bob Biglin and I recognized this as a particular 
challenge and agreed that focusing an engagement on vision and Board efficacy 
would be a useful strategy in avoiding the overwhelming and morbid realities that 
rare disease organizations must overcome.    
Analyzing the effectiveness of employing an Appreciative Inquiry approach 
The DCO engagement centered on building a strategic plan that would 
enable DCO to grow its internal capacity and further deliver on its mission.  As 
we evaluated approaches in working with DCO, Bob Biglin and I both had 
developed a foundational philosophy based on a humanistic approach to 
consulting.  During our initial conversations with DCO’s board, we understood 
that the Board was very much caught in the moment in meeting the needs of 
their constituents.  They lacked the capacity and objectivity to take a step back 
and evaluate their strengths, what they had accomplished, and what challenges 
they would encounter in continuing to move DCO’s mission forward.   
From our initial discussions with the Board, it became clear that there 
were much deeper challenges to be addressed if they were to successfully 
develop and execute a strategy focused on expanding their capabilities and 
outreach.  From these initial observations which included observing board 
fatigue, a lack of a future vision, low self-confidence, low appreciation of previous 
accomplishments.   We felt that an approach informed by Appreciative Inquiry 
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would provide a productive framework for creating momentum for the 
organization and its leadership, through a strengths-based focus.  This approach 
has been the subject of evaluation and analysis since Cooperrider introduced the 
world to his Appreciative Inquiry model. 
When is Appreciative Inquiry Transformational?  A Meta-Case Analysis 
(Bushe, 2005) and  Comparing Appreciative Inquiry to Action Research:  OD 
Practitioner Perspectives (Egan, 2005), are two articles that provide a strong 
foundation to understand when and how AI has been successful as well as its 
limitations. 
When Is Appreciative Inquiry Transformational?  A Meta-Case Analysis 
presents a series of case studies that evaluate whether an AI intervention has 
resulted in transformational change.  In determining if each case was 
“transformational,” the analysis considered whether each case included the 
following two key outcomes (2005, pp. 163-164): 
1. Did the AI intervention result in new knowledge or as more 
typical traditional OD and change management on new ways 
of doing things?  Did it create one or more new lenses 
(images, models, theories) for looking at old issues? 
 
2. Did a “generative metaphor" emerge out of this initiative?   A 
“generative metaphor” is defined in this article, as “sayings 
or phrases that are in themselves provocative and can 
create new possibilities for action that are not previously 
considered.”   
   
The twenty cases examined focused on specific initiatives within 
departments or subsidiaries of large companies.  It found that 35% of the 
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examined cases using an AI approach resulted in what the authors defined as 
“transformational” change.   
 Comparing Appreciative Inquiry to Action Research: OD Practitioner 
Perspectives examines the assumptions, approaches and implications of AI and 
AR for organizational development (OD) from the perspective of OD 
practitioners.  The study includes interviews with OD practitioners to explore the 
strengths and weaknesses of AI compared to those of AR (Egan, p.29).  The 
authors provide qualitative data that highlight the strengths and weaknesses of AI 
and AR approaches and summarize key items as follows (2005, p. 41): 
AI Strengths AR Strengths AI Weaknesses AR Weaknesses 
Refines 
understanding 
about 
organizational 
capacity 
Empowers employees 
and stakeholder to 
actualize change 
Difficult interpersonal 
situations may be 
overlooked  
Process may not 
thoroughly empower 
participants in the 
process to examine the 
breadth of organizational 
capacity 
Helps to override 
previously difficult 
events 
The process can be 
transferred to the 
client for independent 
use 
Dissatisfied organization 
members may withdraw 
from the process 
A clear exploration of 
available opportunities 
could be overshadowed 
by negative perceptions 
or feelings 
Empowers 
employees to 
connect 
interpersonally 
It is iterative or 
repeating allowing for 
continuous 
improvement 
Employees may become 
frustrated with managers 
and executives unwilling 
to discuss important 
challenges being faced 
by the organization 
AR keeps the 
organization moving 
from one unsolved 
problem to another. 
 
Each of these studies stand on their own; however, they are intertwined 
and impactful in regard to considering the effectiveness of an AI approach as 
compared to the more traditional organizational development approaches such 
as action research.  
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Busche’s meta-case analysis seeks to determine if AI leads to 
“transformational” change.  It does not explore in great depth why this may or 
may not be the case.  Busche does not denigrate AI as ineffective when a 
transformational change is not achieved, and recognizes that each individual 
case and the nature of the problem itself may be more or less determinates of 
what is actually transformational (2005, p. 177-178).  Whether the AI process 
facilitates improved organizational learning and performance reaches the 
standard of “transformational” is not clear in this analysis.  It also is not clear 
whether a 35% rate of achieving transformational change compares positively or 
negatively to alternative approaches.  It is worth questioning and following up 
with the 35% of the case studies that did achieve a form of transformational or 
significant change. It would also be worth exploring whether these results were 
sustained any better or worse than a similar set of cases using alternative 
organizational development approaches.   
Schein’s Humble Consulting model demonstrates an emphasis on 
equipping the organization with the ability to generate a series of more modest 
yet impactful adaptive moves rather than bold and obvious transformational 
outcomes.  Schein writes, “If the problem turns out to be complex… the client 
and helper should engage in a dialogue to figure out a feasible adaptive move, 
knowing that this may not solve the problem but will provide some comfort and 
will reveal new information on the basis of which to figure out the next adaptive 
move.”  He continues, “My clients and I will discover that the first real help is my 
enabling them to see the true complexity and messiness of the problem situation 
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and help them to abandon the quick fixes and/or knee-jerk reactions.  Beyond 
that, the real help will be to evolve the right adaptive moves to deal with the 
realities of the situation that I help them to identify”  (Schein, 2016, pp. 23-24).  
Schein’s approach is relevant in generating more sustainable outcomes and 
enabling the organization to grow by building its own capacities.  These are 
critical factors to the success of building a strong and agile nonprofit 
organization. 
In the case of our DCO case study, it is too soon to determine if a 
transformational change within DCO has occurred as a result to our AI 
intervention.  Although we implemented an AI approach with DCO, we also 
consciously deviated from a pure AI approach as we felt we needed to be more 
prescriptive than not in providing an action plan to the organization rather than 
facilitating them through the development of their own plan.  This was a function 
of both time and an assessment of the current organization’s strengths and 
competencies.  The overall result of the DCO engagement was to provide an 
action plan that focused on organizational structure and milestones to enable 
DCO to achieve transformational changes in its future, but not necessarily to 
achieve this change through the intervention.  It would be interesting to 
understand what and if incremental changes from the AI or alternative 
interventions examined in Busche’s analysis occurred prior to the 
transformational changes that he’s quantified in his study.   
Whereas Busche’s meta-case focuses on AI outcomes, Egan’s 
comparison between AI and AR focuses on the strengths and weaknesses of 
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alternative processes.  Egan introduces the idea of whether AI could effectively 
be included with AR or other problem solving approaches.  Egan offers two 
perspectives from practitioners he interviewed for his study (2005, p. 44): 
“We need to embrace the philosophy behind AI, not just use part of it” and, 
“It is important that the strength of AI be tapped, but it is also recognized 
that in some cases it is a consulting approach that can be used in 
conjunction with other approaches.”  
Egan studies the benefits and limitations of the AI approach as compared 
to other approaches.  He is not focused on the outcomes of these interventions 
as Bushe explores.  Egan demonstrates that the process is just as critical in 
facilitating the capacity and growth of the organization to optimize and exceed its 
current state, as is the outcome of the specific engagement.  
Problem solving and challenges facing the organization were not ignored 
as the DCO engagement evolved.  However, they were not the main focus 
towards providing consultation and help. Consistent with the AI process, we 
worked with the Board and other DCO stakeholders to gather data and articulate 
their vision.  Our approach was influenced by the philosophy offered by Edgar 
Schein in his book Helping, as Schein writes,  “At the beginning of any helping 
relationship, and throughout its life, what is crucial is not the content of the 
client’s problem or the helper’s expertise, but the communication process that will 
enable both to figure out what is actually needed“ (2011, p. 66).  Egan’s analysis 
comparing AI and AR examines this process between alternative techniques 
whereas, as our case study demonstrates, a predominant philosophy and 
process may exist, but there is judgment and deviation exerted through its 
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application.  No one size fits all, rather it is incumbent on the consultant or 
organizational development practitioner to understand what approach or 
approaches are most appropriate and tailor a blending of these philosophies to 
best serve the client.  This is achieved through the personalization process that 
Schein describes in Humble Consulting (2016).   
Examining whether AI translates into transformational or incremental 
changes in an organization may not be practical within the scope of this 
capstone.  However, measuring where DCO’s Board was in regard to its vision 
and capacity before and after our intervention may be an indicator of the potential 
learning and transformations they’ve enabled by building their capacity.  
Implementing an AI approach with appropriate variations appeared to be an 
effective way of helping DCO gain energy and momentum from their historic 
successes as well as outline a collective vision towards their future. 
Leadership and Innovation in nonprofit organizations  
Comparing nonprofits with for-profits offers interesting insight in its 
application to the DCO case study.  Through the strategic planning process, 
DCO’s board and constituents collectively articulated a vision that would expand 
its capacity and ability to deliver its mission to a wider patient population.  
Through this process it became apparent that to move this vision forward, DCO 
would have to reengineer its board structure and attract others from within and 
outside of the immediate DC community with committed passion and relevant 
skill sets to focus on specific areas of patient advocacy and support.  Another 
critical element to DCO’s vision was the need to recruit, fund and develop the 
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Executive Director position to transform DCO from a patient group to a 
professional advocacy organization.  Like other nonprofit organizations, DCO 
would have to balance its passion and mission with the governance, skills, and 
leadership attributes that are more commonly found in the for-profit enterprise 
sector.   
In 1989 the Harvard Business Review published Peter Drucker’s What 
Business Can Learn from Nonprofits.  Drucker’s popularity and HBR’s wide reach 
removed some of the stigma associated with nonprofit organizations as they’ve 
often been perceived as inferior to their for-profit counterparts in terms of 
business sophistication and organizational capacity.  Others have followed 
Drucker’s article with more in-depth empirical research and case studies 
specifically focused on nonprofit leadership and efficacy.   
 In Drucker’s 1989 article, he examines how nonprofit organizations have 
become more prominent and illustrates a number of advantages nonprofits have 
leveraged that for-profit enterprises wish they could emulate.  He points out that 
for nonprofits, money is a tool rather than an outcome as it is with for-profit 
enterprises.  He also illustrates how successful nonprofit organizations’ focus on 
mission rather than financial outcomes are more difficult to measure, but also 
have created levels of sophistication in nonprofits that would be beneficial to for-
profit entities.  Drucker writes, “Starting with the mission and its requirements 
may be the first lesson business can learn from successful nonprofits.  It focuses 
the organization on action.  It defines the specific strategies needed to attain 
crucial goals.  It creates a disciplined organization. It alone can present the most 
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common degenerate disease of an organization… splintering their already limited 
resources on things that are “interesting” or look “profitable” rather than 
concentrating on a very small number of productive efforts (1989, p. 3).”  
 Drucker’s focus on the role of a nonprofit board and their CEO or 
Executive Director is relevant to recommendations in the DCO case study.  As a 
CEO from a rare-disease pharmaceutical company emphasized in an interview 
that was part of DCO’s strategic planning process explained, “An effective 
Executive Director will transform the grass-root patient-driven group to a 
professional advocacy organization.”  Drucker points out the dynamics of the 
relationship between non-profit CEOs and their Board counterparts as he writes, 
“Nonprofit organization CEOs complain that their board “meddles.”  The 
directors, in turn, complain that the management “usurps” the board’s function.  
This has forced an increasing number of nonprofit organizations to realize that 
neither the board nor CEO is “the boss.”  They are colleagues, working for the 
same goal but each having a different task.  And they have learned that it is the 
CEO’s responsibility to define the tasks of each, the board’s and his or her own” 
(1989, p. 4). This was a point of emphasis throughout the DCO case study as on-
boarding an Executive Director who reports to and works independently from the 
Board will be a critical success factor in building DCO’s capacity and resources.     
 Another area that Drucker addresses is community engagement and 
training.  He emphasizes the importance of a clear mission and providing 
members and volunteers with the training and resources to enable them to 
effectively engage and add value to the organization.  Drucker understands that 
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volunteers and employees, who may have sacrificed some of the drawings from 
the for-profit sector, do so as they often find self-fulfillment and value by working 
for a mission important to them and that will often help others.  As Victor Frankl 
writes in his teaching of existentialism and finding meaning, “curing the soul by 
leading it to find meaning in life” (1963, p.7) is often the motivation of those that 
choose to engage with nonprofit, mission-based organizations.  Drucker 
characterizes this as moving from a force of nonprofit volunteers to one of unpaid 
professionals.  He writes, “What the nonprofit contribute to the volunteer is as 
important as what the volunteer contributes to the nonprofit” (1989, p. 6).  
Drucker emphasizes that volunteer professionals are not satisfied with just being 
helpers, but they thirst for much more and desire.  Many nonprofit volunteers are 
knowledge workers in their own profession and they wish to be the same in their 
contribution to society.  How nonprofits are able to leverage these dedicated and 
compassionate resources into innovation and transformational change that drives 
growing organizational capacity in the nonprofit sector is the subject of research 
and analysis that had followed Peter Drucker’s article. 
Inspired by Peter Drucker’s work, Frances Hesselbien, a Girl Scout Troop 
leader in York, Pennsylvania implemented Drucker’s philosophies with her local 
troop.  Her success in doing so caught the attention of the Girl Scouts of the USA 
organization, and she became its CEO in 1965 where she grew the Girl Scouts to 
a membership of over 2.25 million members and 780,000 employees until she 
was recruited by Drucker to run his Leader to Leader Institute in 1976.  
Hesselbein, now 102 years old continues to lead this organization, now named to 
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Frances Hesselbein Leadership Institute, where she remains their CEO (Leahey, 
2011).   In her video Frances Heisselbein on Her Journey with Peter Drucker, 
Hesselbein shares her first interaction with Drucker in 1968 as she recalls him 
addressing her Girl Scout organization by saying, “You do not see yourselves 
“life-size”; you do not appreciate the significance of the work you do.  Society 
pretends to care for its children and it does not.  For a little while you give a girl a 
chance to be a girl in a society that forces her to grow up too soon.”  
Hesselbein’s and Drucker’s relationship continued to grow and Hesselbein 
recalls an interview with Drucker in the New York Times where Drucker says that 
the Girl Scouts are the best managed organization in the country.  The 
interviewer interjects, “you mean in the nonprofit sector” and Drucker corrects 
him clarifying that they are “simply the best in any sector, anywhere” (Hesselbein, 
2011).  Hesselbein’s Leadership Institute’s homepage describes its mission as to 
“strengthen and inspire the leadership of the social sector and their partners in 
business and government by connecting the public, private and social sectors 
with curated resources and relationships to serve, evolve and lead together.  By 
fostering in 1) the passion to serve; 2) the discipline to listen; 3) the courage to 
question; and 4) the spirit to include, we work to create an open, responsive, 
global social sector.” (http://www.hesselbeininstitute.org/about_us, accessed 
February 9, 2017).  
Drucker’s philosophies and Hesselbein’s application of these demonstrate 
many of the qualities and challenges that were experienced during the DCO 
engagement.  DCO’s needed to take a step back and acknowledge the 
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tremendous work they had produced and celebrate these successes.  Building 
organizational capacity by seeking specific skills that are fueled with passion 
from finding meaning from their mission will help them find those from inside and 
outside their immediate community contribute their skills to the organization.  
Researchers have gone further to examine the specific nonprofit sector attributes 
and leadership qualities that are most effective in this sector. 
Australian Management professors, James Sarros, Brian Cooper and 
Joseph C. Santora in their 2010 Leadership & Organizational Development 
Journal article Leadership vision, Organizational Culture, and Support for 
Innovation in Not-for-profit and For-profit Organizations took Drucker’s ideas a 
step further.   They examined and compared the relationship of nonprofit 
organizations’ social consciousness with the competitive motives found in for-
profit enterprises. They compared each sector’s ability to leverage these different 
motives to build upon leadership, vision, innovation and organizational strength.   
Their study found that for nonprofits, a socially responsible cultural 
orientation mediates the relationship between leadership vision and 
organizational support for innovation.  Alternatively, in for-profit companies, a 
competitive cultural orientation mediates this relationship.  Their research 
includes interviews with nearly 1,500 Australian managers. The study found that 
socially responsible cultures enhance the impact of visionary leaders on 
innovation for nonprofit organizations, while competitive cultures have the same 
impact on for-profit enterprises (2010, p. 301).  This research is important in 
regard to building strategies for building innovative and sustainable organizations 
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in the non-profit sector (2010, p. 291).  Sorrow et al., write; 
The capacity of leaders to define a vision for their organization is one 
thing, but to have that vision accepted and acted upon as anticipated both 
individually and organizationally is quite another proposition.  Additionally, 
on the basis of these findings, the formulation and then implementation of 
vision is a considerably different proposition in for-profit versus nonprofit 
organizations.  We propose that nonprofits are more likely to benefit from 
leader vision that encourages “buy in” to a set of principles that have 
social as well as economical implications and which run counter to the 
commercial imperatives of private enterprises.  The study illustrates that 
organizational cultures play a major role in determining the impact of 
leadership vision on organizational leadership (2010, p. 301).   
This was demonstrated in DCO’s strategic planning process, as their 
constituency looked to the Board to chart the course for DCO’s priorities and 
leadership’s abilities to build upon research, collaboration and patient support 
and wellness.  The process also demonstrated that although the Board and 
members of DCO understood and acted on a common mission, they did not have 
the ability in regard to their perspective or capacity to step away and create a 
story they could share within and outside of their constituency.  DCO had not yet 
fully utilized the strengths of their mission and vision to drive further innovation or 
impact to serve their growing constituency.  The strategic planning process 
helped create awareness within DCO that a vision was needed and leadership at 
the Board would need to transition focus to help articulate and drive vision while 
a future Executive Director would be needed to implement that vision and lead 
the tactical operations of their organization. 
Sarros’ work was informed by the 2004 Nonprofit Management and 
Leadership journal study, Transformational Leadership, Organizational Culture, 
and Innovativeness in Nonprofit Organizations written by Kristina Jaskyte from 
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the University of Georgia’s School of Social Work.  Jaskyte’s exploratory study of 
leadership organizational culture and organizational innovativeness in nonprofits 
sampled 250 employees of the Alabama branch of the Association of Retarded 
Citizens (ARC), an organization that represents over 140,000 individuals with 
developmental disabilities (Jaskyte, 2004).  Although this survey is limited to one 
organization, the ARC is similar to many rare disease advocacy groups, including 
DCO.  Many DCO patients are impacted with mild to severe cognitive disabilities 
and many of the same characteristics of the ARC population are shared with the 
physical and cognitive impacts of rare diseases.   
Jaskyte defines innovation as the ability of organizations to implement an 
idea, service, process, procedure, system, structure or product new to prevailing 
organizational practices (2004, pp. 158-159).  Jaskyte’s research examines the 
correlations between the ARC’s capacity to be innovative with characteristics 
implicit with what is defined as transformational leadership.  Jaskyte defines 
transformational leadership as a set of practices employed for developing 
relationships between leaders and employees.  She defines organizational 
culture as the set of shared values that help organizational members understand 
organizational functioning and thus guide their thinking and behavior.  These 
themes are central to the DCO case study as the success of implementation of 
DCO’s strategy and shared vision is determined to be influenced in large part by 
its ability to transform its board and leadership role to one less centralized that 
will build capacity and drive innovation across its mission.  These concepts are 
innovative to DCO as it has not worked within a shared governance model in the 
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past and will need to garner the resources of its members, partners and their 
contacts to continue to grow in meeting the expanding needs of their 
constituency.   
Similar to Sarros, Jaskyte’s study demonstrated that leadership practices 
that include “inspiring a shared vision,” “enabling others to act,” “encouraging the 
heart” and “modeling the way” were positively correlated with cultural consensus.  
However, the study also surmised that a strong cultural consensus characterized 
by stability and team orientation actually had a negative correlation with 
organizational effectiveness and innovation (2004, p. 162).  The idea that 
innovation and effectiveness is enhanced by a degree of conflict is important as 
DCO’s Board transitions many of its decision-making and implementation 
processes to more regionalized committees and Board sub-committees focused 
on specific areas impactful to their mission.   
Although the data suggests that building a strong collective vision that is 
lead by DCO’s board is counter to increasing their capacity, these factors are 
much more complex.  What Jaskyte’s analysis does support is that leaders must 
enable and empower others within the organization to create vision and 
contribute towards innovation in their own areas, rather than take a top-down 
approach in creating tasks and imploring action.  Creating a sub-committee and 
regional branches of DCO will be catalysts in building DCO’s member and non-
member engagement as well as expand their capacity.  For this approach to be 
successful, DCO’s board must move from one that leads with a top-down or task-
oriented approach to one that enables innovation at the sub-committee and local 
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levels. As Jaskyte cites in a 2001 article, A Strong Cultures and Innovation: 
Oxymoron or Opportunity, by authors Flynn and Chatman, “While some authors 
see strong culture impeding creativity, others argue that when the right values 
are widely shared, a culture will activate creativity and innovation” (2004, p. 163). 
Moving from a small group of doers that provide a single voice to DCO’s 
constituents to a model that facilitates shared leadership across the organization 
will be transformational to DCO.  It is a key success factor in their ability to grow 
their capacity and continue to deliver to its constituents with efficacy.  Peter 
Drucker writes that organizations characterized by deeply embedded leadership 
practices and organizational values risk success because they can stop 
questioning the need to change and respond to the external environment.  With 
growth and success, DCO finds itself in a place where their “reality has changed, 
but the theory of the business (or mission) has not changed with it” (1994. p. 98).  
Drucker’s works are relevant as DCO is no longer focused on a small patient 
group or limited research.  They are becoming a much more impactful 
organization as demonstrated with their ability to influence research, increase 
clinical access, develop a prestigious medical advisory board and publish clinical 
guidelines which have been transformational to its members.  They’ve gotten 
much larger in their accomplishments and to continue this trajectory they must 
move from a small-centralized cadre of leaders to a leadership model that is 
disbursed throughout their organization.   
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Conclusions from a review of the literature 
 Understanding the dynamics, strengths and challenges inherent in 
nonprofit organizations, and rare disease advocacy groups particularly, is an 
important element of equipping a consultant with the correct framing of how to 
best help these organizations.  As described by Peter Drucker and demonstrated 
with case studies and surveys, nonprofit organizations bring the strength of 
compassion and mission that for-profit enterprises are envious to emulate.  
Familiarizing oneself with the brief history of rare disease advocacy also provides 
the consultant with a greater perspective of what unique characteristics and 
challenges their constituencies face and how they respond.  The literature 
documents how leveraging leadership that is fueled with a mission and vision is a 
powerful tool for rare disease boards and executives to influence innovation and 
both transformational and adaptive changes for these to meet the challenges 
they face with limited resources.  Applying an Appreciative Inquiry philosophy 
with appropriate critical analysis and some level of prescriptive acts to 
supplement for areas where DCO may have lacked skill or capacity appeared to 
be an appropriate approach in helping DCO enable its Board and members to 
create a vision and plan that will help them build capacity and resources to 
support the research and wellness that impact their members.   
 The AI literature demonstrates that applying this approach to an 
organizational development consultation was transformational for the DCO 
Board.  This approach helped them recognize their strengths, accomplishments 
and opportunities. 
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CHAPTER 4  
RESEARCH METHODOLOGIES, ASSUMPTIONS, DATA AND ANALYSIS 
Research methodologies and assumptions 
The mission of rare disease advocacy organizations is often life-or-death 
for its members as they focus on helping and supporting those who are very sick.  
As a parent, advocate, former board member and now as consultant to a rare 
disease organization, I have seen the passion and emotion inherent within a 
“kitchen-table” organization both propel and limit the capacity and effectiveness 
of an organization.  Based on my experiences, I thought most, if not all, rare 
disease organizations ran on a shoestring budget and each struggled to fund and 
execute their missions.  I assumed what was not present in skills and experience 
was compensated for in drive and determination.  I also believed a strong Board 
and paid professional Executive Director were must haves for organizations to 
meet the needs of their constituents and influence research and resources 
towards those they advocate.  Through the stories of others, I’ve found some of 
these assumptions, to various degrees to be true, while others were not the case.  
Over the past three years, in large part through participation with the 
University of Pennsylvania’s Orphan Disease Center’s Million Dollar Bike Ride 
and Rare Disease Symposium, I’ve met other leaders in the rare disease 
advocacy community.  Those included in this interview process were some of the 
most innovative and passionate people I’ve ever met.  In addition to those in the 
rare disease community, I had the opportunity to interview the Executive Director 
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of a special needs camp that serves many from the rare disease community.  
Each of those I’ve interviewed shared insights, ideas and experiences.  I am 
honored to be able to include the following individuals amongst those who 
participated in this journey: 
 
Kyle Bryant – an athlete, speaker and 
the spokesperson for the Friedreich's 
Ataxia Research Alliance (FARA). 
 
 
(FARA, 2017) 
 
 
 
Kristin Smedley – a mother and 
advocate for two sons afflicted with 
CRB1-LCA, a rare disease diagnosed in 
less than 300 people in the United 
States.  Kristin is a tenacious advocate, a 
popular speaker and well recognized in 
the rare disease community.   
 
(CRB1.org, 2017) 
 
 
 
Dr. David Fajgenbaum – a patient, 
advocate, physician and faculty 
member at the University of 
Pennsylvania.  Dr. Fajgenbaum 
learned that he suffered from 
Castleman Disease, a rare 
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inflammatory disorder that causes 
hyper-activation of the immune 
system.  
 
(CDCN, 2017) 
 
Anne Catlin – Executive Director of 
Bournelyf Special Camp.  Bournelyf 
Special Camp is a summer educational 
and recreational day camp in West 
Chester, PA, for youth with intellectual 
disabilities and related disabilities.  
   (campbournelyf, 2017) 
 
 
(Annie with her baby in first row)  
 
Robin Huiras & Lisa Helms-Guba – 
DCO’s past President and current 
Treasurer.  Both Robin and Lisa are 
DC patients and have shared their 
knowledge and experiences with 
others within and outside of the DC 
community.  They are both a testament 
to courage, love and empowerment.   
 
 
 
 
(dcoutreach, 2017) 
 
 
  
 
65 
 
 
 
Each person interviewed was asked the same series of questions, their 
answers and responses were open-ended and invited further probing and inquiry 
during each interview.  Below is a list of the questions asked, what the underlying 
purpose was for each question and my own assumptions, right and wrong, that 
were present during these interviews. 
• Describe your journey from when your organization was first formed to 
where they stand now.   
This question was designed to understand the story of their organization.  It 
included their involvement as founders or later members.  Understanding 
where the organization started and their trajectory forward was valuable in 
seeing what resources were essential in building a successful advocacy 
organization. 
My own assumption was that rare disease organizations typically began with 
very limited resources and little sophistication in regard to experiences and 
skills essential to effectively implement their missions.  
• What do you consider its most impactful successes/greatest 
accomplishments? 
This question was asked to understand what types of accomplishments 
leaders felt were most valuable.   
I assumed that leaders would focus on patient support and research.   
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• What contributed to these successes?  What 2-3 things were most 
critical? 
This question was asked with a focus on what skills sets were essential in 
regard to creating transformation or innovation in a nonprofit.   
I assumed that leaders would identify financial and high profile achievements 
that were geared towards curing or bringing wide-scale attention to their 
mission. 
• What challenges lie ahead for your organization?   
This question intended to learn of the areas of focus for vision and capacity 
building for each organization represented.   
I assumed a wide variety of vision as each organization was at a different 
point in their evolution. 
• What would you consider as transformational to your organization?  This 
can include things that have already happened as well as what may lie 
ahead. 
This question searched to understand what leaders viewed as 
transformational and how they viewed smaller, adaptive, steps on the way.   
I assumed each leader would have a different definition of what was truly 
transformative to their organization.   
• Has your organization at any time used a consultant?  If so, what were the 
most and least effective aspects of the consulting engagement? 
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This question was designed to understand the effective or detrimental 
aspects of engaging with a consultant and why rare disease or grass-root 
organizations were different than more traditional organizations for 
consultants.  It was also intended to gain perspective on why an appreciative 
approach and humble consulting methodology would or would not be most 
appropriate for these organizations. 
I assumed that not all organizations had used consultants, but those that had 
would have experienced successes with a collaborative and personalized 
approach between the consultant and the leadership of the organization. 
Similar to the appreciative inquiry approach employed during DCO 
engagement, these questions are designed to celebrate the accomplishments, 
identify opportunities and articulate a vision for each of the subject matter experts 
interviewed.  
Data  
 Each of those interviewed had a unique and courageous story to tell.  
They share attributes of strength, passion, courage and leadership.  Although 
each of their stories are different and their respective organizations are at various 
places in their journey, their focus on service and their desire to make a lasting 
impact that will improve and extend the lives of their constituents brings them 
together.   An aggregation of the data from these interviews is presented in 
Appendix D, below is a brief presentation regarding each journey, from patient or 
caregiver to advocate to nonprofit leader. 
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Kyle Bryant – Friedreich's Ataxia Research Alliance (FARA) 
 
Ten years ago, at the age of 25, Kyle was diagnosed with 
Friedreich’s ataxia.  Friedreich’s ataxia (FA) is a debilitating, life-
shortening, degenerative neuro-muscular disorder. About one in 
50,000 people in the United States have Friedreich's ataxia.  Kyle was a strong 
athlete who excelled in baseball and enjoyed outdoor activities.  Shortly after 
receiving his diagnosis in 2007 he and his family felt that fundraising was a way 
they could feel a sense of empowerment as they were faced with Kyle’s new 
diagnosis.  Kyle soon developed an interest in a recumbent bike and within a 
year ventured to ride across the country with his father.  Kyle’s mom followed in 
the family car and his first ride garnered local and national attention.  Kyle is an 
incredible speaker and inspiration to others within and outside of the rare disease 
community.   
 In 2009, Kyle joined the FARA Board and is currently the Director of 
rideAtaxia and a Director on the FARA Board.  FARA’s Board was strong from its 
inception as its founders included the retired CEO of Outback Steakhouse, a 
retired US Congressman and professionals in the communications, financial and 
legal fields.   These skills have been valuable in setting their mission and focus 
as they continue to grow.  Kyle emphasizes the Boards ongoing capacity as 
being built one relationship at a time.  Setting realistic expectations and a 
constant focus on mission and values has helped steer FARA to its current level 
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of efficacy and they are positioned well to influence further research and provide 
support to their constituents. 
Kristin Smedley – Curing Retinal Blindness 
 Kristin is the mother of two boys affected with a 
mutation of the CRB1 gene.  A condition diagnosed in less than 300 patients in 
the United States and fewer than 1,000 patients globally.  Her involvement 
started when she learned about a clinical trial that a larger “umbrella” disease of 
which CRB1 is related.   When learning of this trial, she knew her children and 
others with the CRB1 mutation needed to be included and through “stalking” and 
persistence, she successfully advocated with fundraising and leveraging the local 
and national media.  Kristin is known to be a consistent force at rare disease and 
optometry conferences.  She is a professional speaker and exudes great energy 
in her work to create awareness for the CRB1 condition and advocating for a 
high standard of life for those impacted with blindness.   
Dr. David Fajgenbaum – Castleman Disease Collaborative Network   
As a medical student at the University of 
Pennsylvania’s Perlman School of Medicine David 
was faced with a sudden and life-threatening 
episode that included his organs shutting down and 
the real prospect that he would not survive what 
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was then an unknown condition.  Three other times he’s had near-death 
experiences from the rare immunological disorder, Castleman Disease.  In 
addition to being a patient advocate, David is also a physician and faculty 
member at the Perlman School of Medicine.  David also completed his MBA at 
Penn’s Wharton School and was the quarterback at Georgetown University when 
an undergraduate student.  In 2012 David partnered with the Castleman 
Awareness and Research Network, which had been founded in 2007and merged 
this existing organization focused on patient support and wellness with his newly 
founded Castleman Disease Collaboration Network (CDCN), which would 
dedicate its mission towards research.  David’s experiences in science, business 
and the nonprofit organization he started at Georgetown to help students cope 
with grief (David lost his mother while an undergraduate student) served to 
implement a plan of collaboration and outreach that has set a model for the 
prioritization of research efforts throughout the world.  David has dedicated his 
life and has offered himself as the personal clinical subject which has advanced 
treatment and research in this rare disease.  He’s an excellent speaker and has 
recently been featured in the New York Times, the medical journal Science and 
other local and national news outlets. 
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Anne Catlin – Bournelyf Special Camp 
  
Anne has been the Executive Director of Bournelyf Special Camp for the 
past ten years.  Bournelyf’s mission of promoting independence, support and 
friendship serves 150 campers and their families each year.  Camper’s range in 
age from seven to several campers in their thirties and forties.  Anne, a special 
education teacher and mother of two, has been a volunteer, counselor and staff 
member at Bournelyf since her older brother Joey started as a camper more than 
twenty years ago.    Bournelyf is a special organization to me as my son Josh 
attended the camp during the last four years of his life.  Since Josh’s death I 
have served on Bournelyf’s Board of Directors and our family has volunteered 
during the summer camp session as well as other events throughout the year.  
Although not focused on rare disease advocacy, Bournelyf serves as an 
excellent example of a grass-root organization that has grown in capacity and 
impact since it’s inception thirty-five years ago.  Campers and families have 
found support and identity with others struggling with Downs Syndrome, autism 
and other cognitive challenges.  Anne has been pivotal in their growth as she is a 
highly networked and knowledgeable Executive Director who has effectively 
Annie & her older brother Joey at a 
Bournelyf event 
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relied on a strong Board to steer and promote the camp’s mission as it has 
evolved with a changing special needs environment.   
Robin Huiras and Lisa Helms-Guba – Dyskeratosis Congenita Outreach, 
Inc. 
  
Robin Huiras and Lisa Helms-Guba are both DC patients and strong 
advocates to the DC community.  Robin had been DCO’s President since 2012 
through 2016.  She is a mother of two and a journalist living in Minneapolis, 
Minnesota.  Robin has brought her reporting and communication skills to DCO as 
she founded their newsletter and ensures they speak with a common voice. Lisa 
has been DCO’s Treasurer since 2011.  She is a retired nurse in the US Air 
Force and mother of a teenager in Annapolis Maryland.   Lisa brings a strong 
medical and scientific background to DCO and is a tireless advocate with an 
appreciation of strong governance and training.  Working together with DCO’s 
other Board members, they have transformed DCO from a small patient support 
group to an advocacy organization that has assembled a top-notch medical 
advisory board,  published a 400-page clinical guideline book that is an extremely 
valuable resource to patients and doctors, influenced research with clinical 
application for DC and other biological telomere disorders and fostered a warm 
and powerful patient community that is focused on outreach and support.  They 
Robin (left), Lisa (right) 
with Dr. Sharon Savage 
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recognize DCO has come a long way and have set a foundation for the 
organization to continue to provide resources and support for its growing base of 
members.  Both Robin and Lisa are fearless and relentless as they manage their 
own health challenges every day along with other family members impacted by 
DC.  In addition to being valuable friends and supporters through Josh’s hardest 
days, they have been incredibly generous in their time and insight towards their 
contributions in this capstone.  
As I interviewed each person, I was in awe of his or her individual story.  
Each person shared openly and each agreed that his or her story should not be 
masked with anonymity.  Each provided generous insight, emotion and feeling as 
they discussed their passion and commitment towards their individual and 
collective mission. What follows is a summary of the data collected by each 
individual for each question asked.  This compilation of data is followed by an 
analysis that presents common themes and unique ideas as they relate to the 
topics of: 
• Building board capacity; 
• moments or changes that were transformational or adaptive to their 
organization; 
• collaboration; and 
• their experiences working with consultants. 
 I was truly blessed with a rock-star line-up of advocates and leaders and 
I’m honored to share their thoughts and visions.
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Analysis 
 Through inquiry and subsequent discussion, each nonprofit leader shared 
their own story and their vision towards the future.  Although each story was 
unique and perspectives differed, there were common themes that ran across 
each of the nonprofit organization experiences.  Topics addressed within the 
interviews included building board capacity and staying focused on mission, the 
role of the patient or caregiver, the importance of collaboration and how each 
organization has worked to fund and influence research.   
• Building Board Capacity 
 Building board capacity and recruiting the support of others was a 
common theme  with each leader interviewed.  This was addressed as a factor of 
success and accomplishment as well as a critical challenge to meet the future 
needs of the organization.  In the case of FARA, Kyle Bryant described a very 
detailed and deliberate process of Board recruitment.  As Kyle described, board 
meetings include a “white-board” session which focuses organizational gaps in 
skills what personal connections could help recruit volunteers to help meet these 
needs.  The FARA board is well established and financially healthy and well 
connected as members include a congressman, a retired CEO of a highly visible 
corporation and several other high-profile individuals.  Their nomination 
committee plays a key role in helping ensure they have access to those with the 
skills necessary to meet the ever-changing needs of their constituents.   
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Anne Catlin, Executive Director of Bournelyf Special Camp (BSC) 
describes the evolution and maturation of BSC as largely dependent on a strong 
board that started with a small group of parents and church members (the camp 
is located on the grounds of a church) and has expanded to include others with 
no affiliation with the church or camp.  These other individuals include a lawyer, 
CPA and an Executive Director of another local nonprofit organization.  Bringing 
in others from outside the camp community has had a tangible impact on 
fundraising, addressing deferred maintenance needs of the camp and 
implementing a solid and sustainable financial strategy.  It has also enabled 
Anne to focus more on developing her staff and implementing impactful 
programs for the campers both during the camp season and during events held 
each month, throughout the year.   
Dr. Fajgenbaum from CDCN has supplemented his Board’s scientific 
focus with volunteers from the University of Pennsylvania’s Wharton School of 
Business.  This has been a critical resource as CDCN has taken a business 
execution approach towards administering a model that drives collaboration 
amongst researchers and reaches broadly to gain access to the global scientific 
community. 
In the case of DCO and CRB1, both organizations have achieved a great 
deal with limited resources.  Much of this has been accomplished on the back of 
a few active caregivers and in the case of DCO, patients.  Leaders from both 
organizations expressed that active board members were reaching “burn-out” 
and as Kristin Smedley put it, they are reaching the “five-year drop-off”.  As 
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demonstrated in the DCO case study, the DCO Board realizes that to continue to 
meet the needs of a growing patient database, it is critical that the Board 
implement a strategic plan that engages others from within and outside the DCO 
community.  By dispersing governance they will have a greater ability to speed 
up execution and accomplish more.  This aligns with the research of Sarrow and 
Jaskyte, which examine transformational leadership, and nonprofit management 
and leadership effectiveness as presented in the literature review.   
The strength of a strong board which could provide leadership in driving 
and accelerating a rare disease organization’s capacity and influence to its 
patients, partner organizations and other collaborators was presented in the DCO 
case study as a “fly-wheel effect” where momentum comes from the center 
leadership of the organization and is provided to those working towards its 
mission.  This was illustrated as follows: 
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• “Transformational Change” and “Adaptive Moves” 
  Two of the rare disease advocacy leaders interviewed acknowledged that 
speed and urgency had a unique emphasized importance to those researching 
and managing rare diseases, but they also recognized that a path to curing a 
disease as Dr. Fajgenbaum described, is a “journey with many steps”.  Dr. 
Fajgenbaum also felt that “it is critical for rare disease organizations to think 
beyond advocacy to scientific impact.” 
Kyle Bryant felt it was important that not everything was measured to the 
standard of a “cure” as there is so much to be done to improve and extend the 
lives of rare disease patients.   Each leader interviewed pointed to incremental 
steps, moments or transformative goals towards advancing the quality of life for 
their patients, families and caregivers.  Generating awareness, whether by 
means of publishing clinical guidelines as is the case with DCO and CDCN or 
what Kyle Bryant refers to as “targeted awareness that brings a measurable 
change” was cited as transformational.  The rare disease organizations value the 
work and results that are tangible, rather than simply creating exposure without 
meaningful outcomes.  Kristin Smedley spoke of a recent US House Resolution 
recognizing “National Rare Eye Disease Day” that was written in braille as a 
transformational moment as its press coverage brought about a great level of 
dialogue to promote the capabilities of those impacted by blindness.   
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Schein’s Humble Consulting model demonstrates an emphasis on 
equipping the organization with the ability to generate a series of more modest 
yet impactful adaptive moves rather than bold and obvious transformational 
outcomes.  Schein writes, “If the problem turns out to be complex… the client 
and helper should engage in a dialogue to figure out a feasible adaptive move, 
knowing that this may not solve the problem but will provide some comfort and 
will reveal new information on the basis of which to figure out the next adaptive 
move” (Schein, 2016, pp. 23-24).  Schein’s words ring true as those interviewed 
shared a perspective that there are many impactful and important steps towards 
improving the quality of lives for those with rare diseases or other challenges that 
often fall short of a “cure.”   
• Collaboration 
Collaboration was another prevalent theme towards building capacity and 
driving outcomes. Kristin Smedley, Robin Huiras and Lisa Helms-Guba spoke at 
length about their organization’s alliances with NORD, the Genetic Alliance as 
well as with other rare disease advocacy organizations.  As many rare disease 
patients may feel alone, organizations often feel lost while advocating for a 
disease that has so few patients.  Rare disease organizations, symposiums and 
networking are all ways that leaders have described as ways of coming together 
and sharing collective views and resources.   
Another area of focus for collaboration is within the medical community.  
This was discussed at length with Kyle Bryant and especially by Dr. Fajgenbaum, 
who is a part of the medical and research community.  Both Kyle and Dr. 
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Fajgenbaum stressed how maintaining the visibility and presence of the rare 
disease patient is a critical factor in driving researchers, who are often perceived 
to be territorial and non-collaborative. In regard to Castleman Disease, Dr. 
Fajgenbaum shares that “getting all doctors to share samples is especially 
difficult.  Good samples are hard to find; disaggregated research at research 
institutions and hospital labs slow things down.  Aggregating this knowledge 
would definitely speed things up, unfortunately, not all researchers are interested 
in doing this.”  Dr. Fajgenbaum created a collaborative research model that has 
been shared throughout the rare disease community.  As both Dr. Fajgenbaum 
and Kyle Bryant emphasize, keeping the patient at the center of research is what 
will facilitate efficient and effective research outcomes.  That feeling was also 
shared by Robin Huiras as she described DCO’s success in recruiting and 
maintaining an extremely knowledgeable and collaborative medical advisory 
board, one of their most significant accomplishments as described by both Robin 
and Lisa Helms-Guba. 
• Nonprofits working with consultants 
Of the five organizations with leaders interviewed, three of them have 
utilized outside consultants.  FARA has used both a fundraising and two PR 
consultants, Bournelyf has used a grant writer and strategic planning consultant 
and DCO had recently engaged Bob Biglin and me as described in the case 
study.   
Kyle Bryant shared FARA’s experience with consultants as mixed.  When 
working with a fundraising consultant, they provided FARA with good ideas and 
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direction that made a difference to their fund raising efforts.  On the two 
occasions of working with PR consultants, Kyle shared that neither went well as 
in both cases the consultant did not understand the values or culture of FARA 
nor did they understand why rare disease organizations are different.  Kyle 
appreciated the personalization process implemented by the fund raising 
consultant.  He also feels that consultants need to be visionary and tactical, 
saying “you can’t have one, you need both.” 
Anne Catlin’s experience with an outside consultant was positive as the 
consultant had a history of working closely with the board and Executive Director 
as a grant writer for a number of years before leading then through a strategic 
planning process.  Again, a high level of personalization had existed before 
jumping into the engagement.  Similar to Kyle, Anne felt that it was important that 
the consultant be a bit prescriptive in terms of outlining a tactical plan after 
leading the Board and camp families to a strategic vision.  She also felt being a 
good listener and working with data and filtering out emotions were valuable 
attributes brought by a third party consultant.  The skills, perspective, and 
organization brought in by a consultant were all valuable elements that Anne 
noted when describing her organization’s positive experience.   
Many of the elements described by Kyle and Anne were also evident 
during the DCO case study.  Robin Huiras, DCO’s President at the time 
described the engagement as “very helpful” and valued the collection of 
synthesized outside information that was gathered and honest feedback that was 
incorporated into goals and outcomes.  Robin also noted that the Board was 
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already aware of their problems and the Appreciative Inquiry approach used in 
the engagement was “spot-on” feeling an Action Research approach would not 
have been nearly as visionary or productive.   
Conclusions 
The stories and perspectives shared by Kyle Bryant, Kristin Smedley, Dr. 
David Fajgenbaum, Anne Catlin, Robin Huiras and Lisa Helms-Guba 
demonstrate that rare disease advocacy and small nonprofit organizations come 
in many different sizes and have a varied set of resources and priorities.  The 
single most impactful value each of these organizations and their leaders share 
is the importance of keeping the patient (or camper) first and in the forefront of 
their mission and accomplishments.  This is an important success factor as it has 
been shown to drive collaboration and urgency, both critical elements in 
facilitating research and outcomes for those struggling with diseases or 
conditions that compromise their quality life and in many cases survival.  Each 
organization has also demonstrated and valued the benefit of a strong and 
diverse board.  In the case of FARA and CDCN, their Boards already include 
active and passionate individuals with an abundance of access to others who can 
help their organizations.  In the case of DCO and CRB1, they are in the earlier 
stages of building this capacity, but have a clear vision and plan in regard to how 
to build upon their previous successes and engage others who can ensure the 
growth and sustainability of their mission and organization.  In the case of 
Bournelyf, their Board and community engagement has facilitated significant 
growth and financial stability over the past five years and they are now positioned 
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to begin building endowments and address long-term challenges that will secure 
the future of the camp for future generations.   
Passion, drive, urgency, resilience, commitment, creativity and tenacity 
are all attributes found in each of those interviewed.  As rare disease patients 
and caregivers face unique stressful challenges, it has been demonstrated that 
employing a visionary and strength-based approach towards working with them 
as a consultant or subject matter expert is an effective way of working towards 
positive outcomes when faced with very life-and-death medical and wellness 
issues.   
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CHAPTER 5 
CONCLUSIONS AND AREAS OF FURTHER DISCOVERY 
 Being a part of the rare disease community as a caregiver, bereaved 
parent, advocate, consultant and now as an executive coach has been the most 
tragic and rewarding part of my life over the past twenty-two years.  As parents 
and caregivers, my wife and I lived through an incredible life that our son gave to 
our family, friends and community.  We came to understand our own resilience 
and frustration as we looked for an explanation for why our son was not growing 
or thriving.  When we found that answer with a diagnosis of a rare disorder, we 
were determined to enable Josh to continue to live a happy and productive life 
and avoided projecting what the future may hold for him as much as we could.  
When Josh’s health began to deteriorate, we found ourselves working with more 
urgency to connect with the few doctors and families that understood our 
circumstance.  We found a small and passionate community that was there to 
help us and ensure we were exploring every option and receiving the best care 
available for our son.  After losing Josh to this devastating disease, I found 
joining a Board that was working to advocate provided some healing and an 
opportunity to tribute Josh, but eventually that became an impediment to coping 
and living.  At this time, I realized I could be much more effective in the DC and 
rare disease community as a consultant and coach who could provide 
perspective and counsel to help build and sustain a rare disease organization.  
This capstone has provided a path to the next steps in this journey, one that has 
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been inspired by my son and those that I’ve met at Penn and within the orphan 
disease community.   
 The DCO case study examined my own personal journey and how a small 
rare disease advocacy organization has been able to assemble an exceptional 
medical advisory board and tirelessly work to support a growing number of 
families who were often at the very beginning of a rare disease diagnosis and 
journey.  It also illustrated an organization that relied on very few people, each 
either sick from the disease or relentlessly caring for a loved one that was 
impacted with DC.  Our consulting engagement with DCO exemplified a focus on 
the positive and created a future vision to serve a community that is in great fear 
and often despair in regard to the sorrow they encounter every day.  We found 
this approach to be effective as it enabled DCO’s leaders to develop a plan that 
would require the help of others and build a board with the capacity to move 
towards their vision of influencing more research and growing its resources to 
support a growing number of patients and families.    
 The review of existing literature helped develop an understanding of what 
separates rare disease advocacy organizations from other small nonprofit 
organizations.  Looking back at the history of the Rare Disease Act of 1983 and 
how a few high-profile advocates were able to draw attention to this population 
helped outline the unique challenges experienced when working towards bringing 
attention to diseases that singularly are small in patient numbers, but collectively 
represent one-in-ten individuals in the world’s population.  The review examined 
what makes the nonprofit sector special as compared to the for-profit enterprise 
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sector.  Examining the work of Peter Drucker and his influence upon Frances 
Hesselbein as well as subsequent research into effective elements of leadership 
and innovation in the nonprofit sector provided a template to further understand 
successful ingredients of building capacity for nonprofit organizations.  Lastly, 
examining the consultant’s role in working with nonprofit organizations was 
outlined in a review of the works of Penolope Cagney and Edgar Schein.  
Schein’s philosophy of developing a helping relationship with a strong level of 
personalization and partnering proved to be critical in providing effective 
consultation to rare disease advocacy organizations as was demonstrated in the 
DCO case study as well as in interviews with leaders of other nonprofit 
organizations that were included in this capstone.  This was further expanded 
upon when examining the effectiveness of an Appreciative Inquiry approach as 
compared to more traditional Action-Research techniques in consulting.   
 The final section of this capstone offered insights, opinions and incredible 
stories from leaders of five small nonprofit organizations, four of them from the 
rare disease community and the fifth from a camp that services many from this 
same community.  The importance of building organizational capacity and 
acquiring people with relevant skill sets to help these “kitchen-table” 
organizations are needed to supplement the efforts of a patient-centric board 
resonated with each interview.  The importance of collaboration within the 
medical community and working to influence the science and research that was 
being done was another theme that was shared amongst multiple people of 
those interviewed.  There is a common understanding that urgency and the need 
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to move forward quickly are paramount and unique to rare disease organizations 
as speed is truly a life-or-death issue.  Most of all, each organization’s leader 
shared the importance of having the patient and caregiver at the center of 
everything that was done.  There is a high level of self-advocacy within the rare 
disease community and for others to help, whether as a consultant, paid 
employee or volunteer, compassion and personalization of the patient’s struggle 
is an essential ingredient to effectively help these organizations grow and thrive.   
 The capstone study explores a broad array of issues and complexities in 
regard to nonprofit organizations and specifically those in the rare disease 
community.  Since Peter Drucker’s 1989 Harvard Business Review article, What 
Businesses Can Learn From Nonprofits, there has been a great deal more 
written and researched about the subject.  Unfortunately, there has not been a 
mass of research in regard to rare disease advocacy organizations.  The DCO 
case study serves as one example of work done with this community, but it is 
only one example.  Future focus on these organizations would be valuable in 
helping leaders and practitioners in this community understand what processes 
and techniques are most effective.  In regard to examining what constitutes 
transformational or innovative change within nonprofit organizations, further 
definition of what truly is transformational or innovative and the cause and effect 
of incremental steps in these cases would be relevant to the rare disease 
community.   As the DCO case took place less than a year ago, it is too soon to 
access what changes were made and the results of these changes since the 
consulting engagement ended.  As I have remained involved with DCO and I am 
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currently working as a coach to their new President, I do believe they will follow 
through on a number of the recommended steps towards meeting the vision 
they’ve outlined. 
 As someone who aspires to be a professional coach and consultant, and 
as a member of the rare disease community, I feel very privileged to have 
participated in this Capstone experience.  The work and theories applied during 
the DCO experience and the insights gained from other research and literature, 
as well as the tremendous individuals I interviewed and learned from, have 
positioned me to continue to grow and help others not only in the rare disease 
community, but also in all sectors and professions.  This has been a very 
personal journey for me.   Coaching and consulting is centered on relationships 
and compassion.  I look forward to continuing this journey as I give back to this 
community as a coach and consultant. 
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USING APPRECIATIVE INQUIRY FOR SUSTAINABLE CHANGE 
 
APPRECIATIVE INQUIRY (AI) IS A VISION-BASED APPROACH OF OPEN DIALOGUE THAT IS DESIGNED 
TO HELP ORGANIZATIONS AND THEIR PARTNERS CREATE A SHARED VISION FOR THE FUTURE. 
 
 
 
▸ It is highly participative, building stronger relationships in the 
organization and with partners. 
▸ It is future focused. 
▸ It fosters optimism and hope. 
▸ It draws on the resources, and resourcefulness of the organization. 
▸ It focuses on the positive to crowd out the negative. 
▸  It builds organizational capacity beyond existing boundaries. 
Appreciative Inquiry is about the co-evolutionary search for the best in people, their 
organizations, and the relevant world around them. In its broadest focus, it involves 
systematic discovery of what gives “life” to a living system when it is most alive, most 
effective, and most constructively capable in economic, ecological, and human 
terms. 
- David Cooperrider 
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AI CHANGE STRATEGIES USE THE SOAR FRAMEWORK 
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POSITIVE QUESTIONS AND DIALOGUE ARE AT THE HEART OF AI DRIVEN CHANGE 
 
PROPOSED QUESTIONS FOR DCO CONVERSATIONS 
▸ What are you most proud of that DCO has accomplished? 
▸ What is your most positive memory of time working with DCO? 
▸ When DCO is working at its best, how would you describe that? 
What happens, who’s involved, what are the results? 
▸ In your ideal world, what does DCO look like in five years? 
▸ Can you describe DCO’s biggest strengths? 
▸ What are the capabilities of the organization that you want to strengthen the 
most? 
▸ Who are partners that have the greatest impact on DCO’s success? 
▸ What partnerships could be developed to enhance DCO success? 
▸ When DCO is at its best, what are the core factors or strengths that give life to 
DCO? 
▸ What stakeholders have benefited the most from DCO? 
▸ What stakeholders could DCO reach out to and expand their impact? 
▸ What are the most valuable attributes contributed by DCO’s Board Members? 
▸ What additional attributes or skills would you like others to bring to the Board? 
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DCO CONSULTING ENGAGEMENT SCOPE & TIMELINE (1 OF 2) 
 
Wednesday, July 27th 9PM ET – Introduction Call with Board President, Treasurer and Secretary 
▸ Background and history of DC Outreach, Inc. 
▸ Identify Stakeholders, Resources and Needs 
▸  Outline timeline and objectives of engagement 
▸ Outline data gathering process and timeline 
▸ Design questions for those interviewed 
▸  Format and participation for interviews 
▸ Identify other data resources 
 
Sunday, August 7th, 9PM ET – DCO Board Meeting 
▸  Introduce engagement 
 
▸ Monday, July 25 – Friday, September 2 
▸ Interviews with Key Stakeholders & possible resources; include: 
▸ Board Members 
▸  DCO Families – include international  (Pacific) 
▸ Medical Advisors 
▸  Pharma (Vin Milano) 
▸ Penn’s Orphan Disease Center (Dr. Wilson, Samantha Charleston, Monique Molloy) 
▸ Other
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DCO CONSULTING ENGAGEMENT SCOPE & TIMELINE (2 OF 2) 
 
Sunday, September 4th – DCO Board Meeting 
▸ Update Board 
 
Saturday, September 17 – Sunday, September 18 – Camp 
Sunshine 
▸ Share data with stakeholders 
▸ Develop and Design future state of DC Outreach 
▸ Build commitment and participation towards the future 
▸  Develop actionable objectives and establish ownership and 
milestones 
 
Sunday , October 2nd, 9PM ET – Board Meeting 
▸ Share draft of strategic plan and agree on next steps
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APPENDIX B 
CAMP SUNSHINE PRESENTATION
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APPENDIX C  
DCO ACTION PLAN 
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Key Activities Target Milestone 
Prioritize 
operations, 
sustain 
critical 
functions 
 
Establish 
Regional 
Chapters 
Establish 
Committees 
Solicit 
Volunteers 
Fundraising & 
Development 
Hire Part-
time 
Executive 
Director 
Send Call to Action email to DCO Community 
October 2016 
    
 
Survey to DCO Community to prioritize most 
critical activities to sustain, and frequency of 
activities 
October 2016 
 
    
Launch Fundraising campaign to raise funds for 
part-time Executive Director  
Nov 2016– Feb 2017    
 
 
Review geographic concentrations of DCO 
members and identify potential Chapter regions.   
November 2016  
 
   
Develop Summary Description of Regional Chapter 
and Chapter leads 
December 2016  
 
   
Transition Board Presidency from Robin to Katie 
January 2017 
 
    
Email DCO community, targeting members by 
region, soliciting volunteers to start and lead 
Regional Chapters. 
January 2017  
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Develop Job Description for Executive Director 
January 2017     
 
Explore sources for Exec Dir candidates with 
partner groups (NORD, Global Genes, etc.) 
January 2017     
 
Exec Director candidate search and interviews 
February – May 2017     
 
Hold kickoff conference call with Regional Chapter 
leads 
March 2017  
 
   
Key Activities Target Milestone 
Prioritize 
operations, 
sustain 
critical 
functions 
 
Establish 
Regional 
Chapters 
Establish 
Committees 
Solicit 
Volunteers 
Fundraising & 
Development 
Hire Part-
time 
Executive 
Director 
Hire and onboard part-time Executive Director 
May 2017     
 
Develop scope of responsibilities and key skills for 
each DCO Committee: Communication, 
Development, Wellness & Advocacy, Medical, 
Nominating 
July 2016      
Enlist Regional Chapter Leaders to communicate 
goals and needs of Committees to their respective 
chapters, seeking volunteers and support.   
August 2016   
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Establish Committee charters 
August 2016   
 
  
Launch DCO functional committees 
September 2016   
 
  
 
 
129 
 
 
 
 
 
 
 
 
APPENDIX D  
AGGRETATION OF INTERVIEW DATA 
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Data – The following is an aggregation of data from interviews conducted between February 1 – 15, 2017 
 
 Interview A Interview 2 Interview 3 
What do you 
consider the most 
impactful 
successes/greatest 
accomplishments? 
 
• Not one or two things 
• Founding Board & President.  Relationships 
built one at a time. 
• Relationships with neighbors, friends, co-
workers,etc. 
• Allow patient to have the choice to be 
involved. 
• Went from a disorder nobody heard of or 
thought about to one of the first that 
ophthalmologists now think about 
• In 2016 local congressman submitted a 
resolution on Rare Disease Day in braille – very 
significant; Generated a lot of press; water-
shed moment. 
 
 
 
• Initially the disease was thought about and 
treated like cancer; Understood more with 
other physicians that it is an immune disorder, 
not a cancer. Reframed treatment & research. 
• Recent development of a diagnostic model for 
the disease, online now, soon to be published 
in a leading hematology journal. 
• Until recently, most clinical data came from 
David.  Discovered pathway that personalized 
treatment. 
 
What contributed 
to these 
successes? 
• Creating a patient community 
• Integrity – Each meeting starts with their core 
values  
• Mission, Vision, Strategic Plan used as a guide 
• Bringing others to Board & organization with 
relevant skill sets. 
• What are gaps; who do they need; identify 
personal connections – done on a white board 
 
• Does not like the term “awareness” but does 
believe in moving awareness into action 
• Effective collaboration.  Very visible in rare 
disease community; speaks at symposiums 
and is seen & heard. 
 
• Global community of researchers and 
physicians connected; trust & know the global 
community 
• Huge involvement of patients.  Patients 
involved with the whole process 
• Execution – developed a plan with many steps; 
Not focused on “cure”, but many steps along 
the way.  Break down and execute like a 
business plan. 
• 2 mains sources of volunteer:  
o Patient Communities 
o Penn Community (Wharton & Med. 
Students) 
What challenges 
lie ahead for your 
organization? 
• Managing expectations 
• Not judging everything in regards to if it’s a 
“cure”; not healthy thinking. Recognize value 
of incremental steps. 
• Time is a barrier.  Urgency a core value.  
Speeding business deals & science process is 
life-or-death. 
• Funding/money is a problem that can be 
figured out. 
• Growing too fast, volunteer dropping (5-year 
drop-off). 
• Need professional help in certain areas. 
• Open a Center of Excellence for patient care. 
 
• Getting all doctors to share samples.  Good 
samples are hard to find; disaggregated 
research at research institutions, hospital labs.  
Need to gain access and coordinate and 
accelerate research.  Researchers are not 
always interested in doing this. 
131 
 
 
 
 
 
 
 
What would you 
consider 
transformational 
to your 
organization? 
 
 
Interview 1 
 
• Targeted awareness; something measurable 
that brings change. 
• No such thing as a “general public”. 
 
 
Interview 2 
 
• House resolution in braille 
• Difficult as blindness is not life-threatening, 
but has large impact on quality of life 
• Kristin strives to keep blindness in fore-front 
o TED talk in March 
o Writing a book 
o Comcast commercial 
• Resources  & job losses are issues 
• Likes to go to medical stds.to have them 
involved in rare disease groups early; see 
patient perspective 
 
 
Interview 3 
 
• Bringing together patients and physicians 
• Business plan – “International Research 
Agenda” 
• Publishing Diagnostic Criteria 
• Biggest problem in rare disease orgs is 
redundancy and fracturing; too many 
foundations for the same disease; need to 
collaborate and have less organizations for the 
same disease.  Critical to take action, speed 
results. 
• Think beyond advocacy to scientific impact; 
push Drs. Don’t wait. 
Has your 
organization at any 
time used a 
consultant?  If so, 
what were the 
most and least 
effective aspects of 
the consulting 
engagement? 
• Worked with fund raising consultant w/ good 
results.  Had good ideas and direction that 
made a difference. 
• Twice worked with 2 different PR consultants.  
Neither went well.   
o Did not understand values or culture 
o Did not understand why rare disease groups 
are different “because they’re rare” 
• Effective consultants need to be visionary & 
tactical.  Can’t have just one, need both. 
• Have not used a consultant 
Collaboration is key – rare disease orgs 
demonstrate this at high level 
Work together to “Halt the train of sorrow” 
Has utilized Wharton students as consultants.  
Volunteers are like consultants. 
Rare diseases are often neglected, don’t get the 
attention they need. 
Family and patients with disease are more often 
the people in the organization 
Bigger sense of urgency – most meaningful work, 
constants/volunteers are working directly with 
patients 
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 Interview 4 Interview 5 Interview 6 
What do you 
consider the most 
impactful 
successes/greatest 
accomplishments? 
 
• Financial stability – Now able to address 
deferred maintenance, introduce new 
programs and establish endowments 
• Alumni trips – nice trips,  
• Emergence of other leaders within camp staff 
• Strategic plan now being implemented and 
ready for a refresh 
• DCO awarding a grant through Million Dollar 
Bike Ride 
• Clinical Guidelines – collaboration and 
something that had not existed. 
• Lisa started on the Board five years ago; she 
sees the Board now as much more professional 
and accountable. 
• Focus on governance and compliance 
(documentation, tax, insurance, etc.) 
• Clinical Guidelines were a turning point 
• Mail list has grown from 100 to 900 
• Dr. Agarwal & Dr. Savage – developing the 
Telomere consortium 
 
What contributed 
to these 
successes? 
• Alumni families – they see that they are 
provided with quality trips and quality care.  
Buy in from parents & staff 
• Emphasis on quality, sees it now more as a 
parent 
• Moving from shoe-string budget to better 
appearance of quality, safety 
o Replacing vehicles/vans 
o Updating obstacle course 
 
 
• Clinical Guidelines – a lot of patience and 
confidence.  Very slow moving and Robin’s not 
very patient. 
• MDBR/Grant – Be able to ask for help.  Being 
“in need” is not a weakness, others are looking 
for ways to help.  Perseverance. 
• Belief in self.  Humble confidence. Ability to 
convince others they are doing the right things 
to help. 
• Representing the patient is important. Doctors 
are more willing to collaborate, as patients are 
involved. 
• Following a period of internal conflict, there 
was an urgency to firm up the Board or it 
would not survive. 
• Important each member has a role 
 
What challenges 
lie ahead for your 
organization? 
• Funding is always a challenge 
• Dependent on church grounds 
• Meeting needs of what parents want 
• Shifting population from Downs Syndrome to 
broader spectrum of disabilities, mostly autism 
• Spreading awareness.  Growing the group and 
engaging more families. 
• Group needs to find a way to get people 
excited more than every 2 years (Camp).  
Amplifying outcomes.  Put things in the face of 
members, show them it’s a cause worth 
supporting 
• Keep people engaged regardless of where they 
are in the DC process 
• Sustainability – concerned about burn-out 
• Non-board members need to help out more 
o New board member from Camp Sunshine 
will be a great asset 
 
What would you 
consider 
transformational 
to your 
organization? 
• Camp having its own space 
• More frequency of events, particularly for 
alumni 
• Help alumni as adults; concerned about those 
who age out 
• Hiring a paid Executive Director to move our 
mission forward. 
• Funding and influencing a significant grant for 
DC research 
• Involvement of more people, shared vision 
• Not a lot of spare time, current board is maxed 
–out 
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Has your 
organization at 
any time used a 
consultant?  If so, 
what were the 
most and least 
effective aspects 
of the consulting 
engagement? 
Interview 4 
 
• What makes NPO different: 
o Needs more leading; brings in perspective 
and skills 
 
o Camp is not everyone’s first job, secondary 
• Strong understanding of NPO needs 
• Good listener and patient – filter and not easily 
swayed 
• Organize thoughts and ideas 
• Needs focus on succession planning; 
prescriptive with some things 
Interview 5 
 
• Worked with Penn students to develop 
strategic plan (subject of this capstone’s case 
study) 
 
• Very helpful, synthesized outside information; 
were able to get honest feedback and turn into 
outcomes and goals. 
• Concrete ideas; verbalized many things they 
already know. 
• AI approach was “spot on” 
• Board was already aware of their problems; 
would not have been productive to focus on 
them. 
• Group is young and leadership needed 
inspiration. 
Interview 6 
 
• Medical Advisory Board – technical consultants 
• NORAD is a great resource 
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